<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT02209181</url>
  </required_header>
  <id_info>
    <org_study_id>CO-131230135611-CTPA</org_study_id>
    <nct_id>NCT02209181</nct_id>
  </id_info>
  <brief_title>A Dental Pain Study to Test the Effectiveness of a New Pain Reliever Medicine</brief_title>
  <official_title>A Randomized, Double-blind, Placebo- and Active-controlled Trial to Investigate the Single-dose Efficacy, Safety, and Pharmacokinetics of 250 and 1000 mg JNJ-10450232 in Postoperative Dental Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>McNeil Consumer Healthcare Division of McNEIL-PPC, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johnson &amp; Johnson Consumer and Personal Products Worldwide</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the safety and effectiveness one dose of a new pain reliever medicine (JNJ-10450232&#xD;
      at either the 250 or 1000 mg strength) compared with placebo (sugar pill) or acetaminophen&#xD;
      1000 mg after surgical removal of third molars. The primary endpoint will evaluate pain&#xD;
      relief effectiveness up to 6 hours after administration of the study drug.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single-center, randomized, double-blind, placebo- and active-controlled, parallel&#xD;
      group study to evaluate the efficacy, safety and pharmacokinetic profile of JNJ-10450232,&#xD;
      administered as a single dose in capsules (250 or 1000 mg), over a 24 hour period after molar&#xD;
      extractions. Subjects will stay at the research center for ~24 hours after administration of&#xD;
      study drug. Healthy male subjects, ages 18 to 45 years inclusive, will be screened by medical&#xD;
      history, vital signs, an electrocardiogram (ECG), and clinical laboratory tests. Eligible&#xD;
      subjects will return to the clinic on the day of surgery and complete baseline vital signs&#xD;
      and clinical laboratory tests. They will undergo dental extraction of a minimum of three&#xD;
      third-molars and, if qualified, will be randomly assigned to one of four study treatments for&#xD;
      pain.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2014</start_date>
  <completion_date type="Actual">April 2015</completion_date>
  <primary_completion_date type="Actual">April 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Analgesic Efficacy From 0 to 6 Hours After the Dose Using the Time-weighted Sum of Pain Intensity Difference (SPID 0-6)</measure>
    <time_frame>6 Hours</time_frame>
    <description>Time-weighted sum of pain intensity difference by first multiplying each pain intensity difference (PID) score by the time from the previous time point, and adding them together for each scheduled time point within 0-6 hours. Time points included 15 minutes, 30 minutes, 45 minutes, 1 hour, 1.5 hours, 2 hours, 3 hours, 4 hours, 5 hours, and 6 hours. The minimum SPID 0-6 was -30 and the maximum SPID 0-6 was 60, where higher is better. Pain intensity is the amount of pain experienced on a scale of 1-10 (where 1=no pain and 10=very severe pain).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain Intensity Difference From Baseline (PID) Scores at 15 Minutes Post Dose</measure>
    <time_frame>Baseline to 15 minutes post dose</time_frame>
    <description>Pain intensity is the amount of pain experienced on a scale of 1-10 (where 1=no pain and 10=very severe pain). The PID will be derived by subtracting the pain intensity from the baseline pain intensity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Intensity Difference From Baseline (PID) Scores at 30 Minutes Post Dose</measure>
    <time_frame>Baseline to 30 minutes post dose</time_frame>
    <description>Pain intensity is the amount of pain experienced on a scale of 1-10 (where 1=no pain and 10=very severe pain). The PID will be derived by subtracting the pain intensity from the baseline pain intensity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Intensity Difference From Baseline (PID) Scores at 45 Minutes Post Dose</measure>
    <time_frame>Baseline to 45 minutes post dose</time_frame>
    <description>Pain intensity is the amount of pain experienced on a scale of 1-10 (where 1=no pain and 10=very severe pain). The PID will be derived by subtracting the pain intensity from the baseline pain intensity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Intensity Difference From Baseline (PID) Scores at 1 Hour Post Dose</measure>
    <time_frame>Baseline to 1 hour post dose</time_frame>
    <description>Pain intensity is the amount of pain experienced on a scale of 1-10 (where 1=no pain and 10=very severe pain). The PID will be derived by subtracting the pain intensity from the baseline pain intensity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Intensity Difference From Baseline (PID) Scores at 1.5 Hours Post Dose</measure>
    <time_frame>Baseline to 1.5 hours post dose</time_frame>
    <description>Pain intensity is the amount of pain experienced on a scale of 1-10 (where 1=no pain and 10=very severe pain). The PID will be derived by subtracting the pain intensity from the baseline pain intensity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Intensity Difference From Baseline (PID) Scores at 2 Hours Post Dose</measure>
    <time_frame>Baseline to 2 hours post dose</time_frame>
    <description>Pain intensity is the amount of pain experienced on a scale of 1-10 (where 1=no pain and 10=very severe pain). The PID will be derived by subtracting the pain intensity from the baseline pain intensity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Intensity Difference From Baseline (PID) Scores at 3 Hours Post Dose</measure>
    <time_frame>Baseline to 3 hours post dose</time_frame>
    <description>Pain intensity is the amount of pain experienced on a scale of 1-10 (where 1=no pain and 10=very severe pain). The PID will be derived by subtracting the pain intensity from the baseline pain intensity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Intensity Difference From Baseline (PID) Scores at 4 Hours Post Dose</measure>
    <time_frame>Baseline to 4 hours post dose</time_frame>
    <description>Pain intensity is the amount of pain experienced on a scale of 1-10 (where 1=no pain and 10=very severe pain). The PID will be derived by subtracting the pain intensity from the baseline pain intensity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Intensity Difference From Baseline (PID) Scores at 5 Hours Post Dose</measure>
    <time_frame>Baseline to 5 hours post dose</time_frame>
    <description>Pain intensity is the amount of pain experienced on a scale of 1-10 (where 1=no pain and 10=very severe pain). The PID will be derived by subtracting the pain intensity from the baseline pain intensity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Intensity Difference From Baseline (PID) Scores at 6 Hours Post Dose</measure>
    <time_frame>Baseline to 6 hours post dose</time_frame>
    <description>Pain intensity is the amount of pain experienced on a scale of 1-10 (where 1=no pain and 10=very severe pain). The PID will be derived by subtracting the pain intensity from the baseline pain intensity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Intensity Difference From Baseline (PID) Scores at 7 Hours Post Dose</measure>
    <time_frame>Baseline to 7 hours post dose</time_frame>
    <description>Pain intensity is the amount of pain experienced on a scale of 1-10 (where 1=no pain and 10=very severe pain). The PID will be derived by subtracting the pain intensity from the baseline pain intensity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Intensity Difference From Baseline (PID) Scores at 8 Hours Post Dose</measure>
    <time_frame>Baseline to 8 hours post dose</time_frame>
    <description>Pain intensity is the amount of pain experienced on a scale of 1-10 (where 1=no pain and 10=very severe pain). The PID will be derived by subtracting the pain intensity from the baseline pain intensity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Intensity Difference From Baseline (PID) Scores at 9 Hours Post Dose</measure>
    <time_frame>Baseline to 9 hours post dose</time_frame>
    <description>Pain intensity is the amount of pain experienced on a scale of 1-10 (where 1=no pain and 10=very severe pain). The PID will be derived by subtracting the pain intensity from the baseline pain intensity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Intensity Difference From Baseline (PID) Scores at 10 Hours Post Dose</measure>
    <time_frame>Baseline to 10 hours post dose</time_frame>
    <description>Pain intensity is the amount of pain experienced on a scale of 1-10 (where 1=no pain and 10=very severe pain). The PID will be derived by subtracting the pain intensity from the baseline pain intensity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Intensity Difference From Baseline (PID) Scores at 11 Hours Post Dose</measure>
    <time_frame>Baseline to 11 hours post dose</time_frame>
    <description>Pain intensity is the amount of pain experienced on a scale of 1-10 (where 1=no pain and 10=very severe pain). The PID will be derived by subtracting the pain intensity from the baseline pain intensity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Intensity Difference From Baseline (PID) Scores at 12 Hours Post Dose</measure>
    <time_frame>Baseline to 12 hours post dose</time_frame>
    <description>Pain intensity is the amount of pain experienced on a scale of 1-10 (where 1=no pain and 10=very severe pain). The PID will be derived by subtracting the pain intensity from the baseline pain intensity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Intensity Difference From Baseline (PID) Scores at 16 Hours Post Dose</measure>
    <time_frame>Baseline to 16 hours post dose</time_frame>
    <description>Pain intensity is the amount of pain experienced on a scale of 1-10 (where 1=no pain and 10=very severe pain). The PID will be derived by subtracting the pain intensity from the baseline pain intensity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Intensity Difference From Baseline (PID) Scores at 24 Hours Post Dose</measure>
    <time_frame>Baseline to 24 hours post dose</time_frame>
    <description>Pain intensity is the amount of pain experienced on a scale of 1-10 (where 1=no pain and 10=very severe pain). The PID will be derived by subtracting the pain intensity from the baseline pain intensity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Relief (PAR) Scores at 15 Minutes Post Dose</measure>
    <time_frame>15 minutes post dose</time_frame>
    <description>Pain relief is the amount of pain relief on a scale of 1-10 (where 1=no relief and 10=complete relief).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Relief (PAR) Scores at 30 Minutes Post Dose</measure>
    <time_frame>30 minutes post dose</time_frame>
    <description>Pain relief is the amount of pain relief on a scale of 1-10 (where 1=no relief and 10=complete relief).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Relief (PAR) Scores at 45 Minutes Post Dose</measure>
    <time_frame>45 minutes post dose</time_frame>
    <description>Pain relief is the amount of pain relief on a scale of 1-10 (where 1=no relief and 10=complete relief).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Relief (PAR) Scores at 1 Hour Post Dose</measure>
    <time_frame>1 hour post dose</time_frame>
    <description>Pain relief is the amount of pain relief on a scale of 1-10 (where 1=no relief and 10=complete relief).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Relief (PAR) Scores at 1.5 Hours Post Dose</measure>
    <time_frame>1.5 hours post dose</time_frame>
    <description>Pain relief is the amount of pain relief on a scale of 1-10 (where 1=no relief and 10=complete relief).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Relief (PAR) Scores at 2 Hours Post Dose</measure>
    <time_frame>2 hours post dose</time_frame>
    <description>Pain relief is the amount of pain relief on a scale of 1-10 (where 1=no relief and 10=complete relief).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Relief (PAR) Scores at 3 Hours Post Dose</measure>
    <time_frame>3 hours post dose</time_frame>
    <description>Pain relief is the amount of pain relief on a scale of 1-10 (where 1=no relief and 10=complete relief).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Relief (PAR) Scores at 4 Hours Post Dose</measure>
    <time_frame>4 hours post dose</time_frame>
    <description>Pain relief is the amount of pain relief on a scale of 1-10 (where 1=no relief and 10=complete relief).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Relief (PAR) Scores at 5 Hours Post Dose</measure>
    <time_frame>5 hours post dose</time_frame>
    <description>Pain relief is the amount of pain relief on a scale of 1-10 (where 1=no relief and 10=complete relief).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Relief (PAR) Scores at 6 Hours Post Dose</measure>
    <time_frame>6 hours post dose</time_frame>
    <description>Pain relief is the amount of pain relief on a scale of 1-10 (where 1=no relief and 10=complete relief).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Relief (PAR) Scores at 7 Hours Post Dose</measure>
    <time_frame>7 hours post dose</time_frame>
    <description>Pain relief is the amount of pain relief on a scale of 1-10 (where 1=no relief and 10=complete relief).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Relief (PAR) Scores at 8 Hours Post Dose</measure>
    <time_frame>8 hours post dose</time_frame>
    <description>Pain relief is the amount of pain relief on a scale of 1-10 (where 1=no relief and 10=complete relief).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Relief (PAR) Scores at 9 Hours Post Dose</measure>
    <time_frame>9 hours post dose</time_frame>
    <description>Pain relief is the amount of pain relief on a scale of 1-10 (where 1=no relief and 10=complete relief).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Relief (PAR) Scores at 10 Hours Post Dose</measure>
    <time_frame>10 hours post dose</time_frame>
    <description>Pain relief is the amount of pain relief on a scale of 1-10 (where 1=no relief and 10=complete relief).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Relief (PAR) Scores at 11 Hours Post Dose</measure>
    <time_frame>11 hours post dose</time_frame>
    <description>Pain relief is the amount of pain relief on a scale of 1-10 (where 1=no relief and 10=complete relief).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Relief (PAR) Scores at 12 Hours Post Dose</measure>
    <time_frame>12 hours post dose</time_frame>
    <description>Pain relief is the amount of pain relief on a scale of 1-10 (where 1=no relief and 10=complete relief).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Relief (PAR) Scores at 16 Hours Post Dose</measure>
    <time_frame>16 hours post dose</time_frame>
    <description>Pain relief is the amount of pain relief on a scale of 1-10 (where 1=no relief and 10=complete relief).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Relief (PAR) Scores at 24 Hours Post Dose</measure>
    <time_frame>24 hours post dose</time_frame>
    <description>Pain relief is the amount of pain relief on a scale of 1-10 (where 1=no relief and 10=complete relief).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Pain Relief After Dosing (Time to Rescue Medication)</measure>
    <time_frame>Completed at time of the first rescue medication (hours post dose), estimated up through Day 2</time_frame>
    <description>Time (minutes) to rescue medication was measured as the elapsed time from when the investigational product was given until the time rescue medication was given.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject Global Evaluation</measure>
    <time_frame>Completed at hour 12 or at time of the first rescue medication (hours post dose).</time_frame>
    <description>How the subject would rate the study medication as a pain-reliever on a scale of 0-4 (where 0=poor and 4=excellent).</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">269</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>JNJ-10450232 250 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>JNJ-10450232 1000 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Acetaminophen 1000 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>JNJ-10450232 / Not yet marketed</intervention_name>
    <description>Subjects who meet the randomization criteria at baseline within 4.5 hours after dental surgery will be assigned to one of four treatment groups stratified by pharmacokinetic blood sampling schedule and by baseline pain intensity level.</description>
    <arm_group_label>JNJ-10450232 250 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>JNJ-10450232 / Not yet marketed</intervention_name>
    <description>Subjects who meet the randomization criteria at baseline within 4.5 hours after dental surgery will be assigned to one of four treatment groups stratified by pharmacokinetic blood sampling schedule and by baseline pain intensity level.</description>
    <arm_group_label>JNJ-10450232 1000 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>JNJ-10450232 / Not yet marketed</intervention_name>
    <description>Subjects who meet the randomization criteria at baseline within 4.5 hours after dental surgery will be assigned to one of four treatment groups stratified by pharmacokinetic blood sampling schedule and by baseline pain intensity level.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>acetaminophen / Tylenol</intervention_name>
    <description>Subjects who meet the randomization criteria at baseline within 4.5 hours after dental surgery will be assigned to one of four treatment groups stratified by pharmacokinetic blood sampling schedule and by baseline pain intensity level.</description>
    <arm_group_label>Acetaminophen 1000 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects aged 18-45 years&#xD;
&#xD;
          -  At least moderate dental pain assessed by a categorical scale pain intensity scale and&#xD;
             a score of at least 5 on the 11-point (0-10) pain intensity numerical rating scale&#xD;
             (PI-NRS) following surgical removal of three third-molars&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects who are not otherwise healthy&#xD;
&#xD;
          -  Test positive for the urine drug screen&#xD;
&#xD;
          -  Taking prohibited medications will not be allowed to participate in this study&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Derek Muse, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jean Brown Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Cathy Gelotte, Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>McNeil Consumer Healthcare Division of McNEIL-PPC, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jean Brown Research</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <study_first_submitted>July 22, 2014</study_first_submitted>
  <study_first_submitted_qc>August 1, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 5, 2014</study_first_posted>
  <results_first_submitted>October 12, 2016</results_first_submitted>
  <results_first_submitted_qc>December 10, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 3, 2017</results_first_posted>
  <disposition_first_submitted>February 29, 2016</disposition_first_submitted>
  <disposition_first_submitted_qc>April 11, 2016</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">May 6, 2016</disposition_first_posted>
  <last_update_submitted>December 10, 2016</last_update_submitted>
  <last_update_submitted_qc>December 10, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 3, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>dental pain</keyword>
  <keyword>post-surgical dental pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Toothache</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetaminophen</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Three placebo capsules taken orally</description>
        </group>
        <group group_id="P2">
          <title>Acetaminophen 1000 mg</title>
          <description>Two encapsulated 500 mg tablets and one placebo capsule taken orally</description>
        </group>
        <group group_id="P3">
          <title>JNJ-10450232 250 mg</title>
          <description>One JNJ-10450232 250 mg capsule and two placebo capsules taken orally</description>
        </group>
        <group group_id="P4">
          <title>JNJ-10450232 1000 mg</title>
          <description>One JNJ-10450232 250 mg capsule, one JNJ-10450232 750 mg capsule, and one placebo capsule taken orally</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="67"/>
                <participants group_id="P2" count="67"/>
                <participants group_id="P3" count="69"/>
                <participants group_id="P4" count="66"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="66"/>
                <participants group_id="P2" count="66"/>
                <participants group_id="P3" count="68"/>
                <participants group_id="P4" count="66"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Three placebo capsules taken orally</description>
        </group>
        <group group_id="B2">
          <title>Acetaminophen 1000 mg</title>
          <description>Two encapsulated 500 mg tablets and one placebo capsule taken orally</description>
        </group>
        <group group_id="B3">
          <title>JNJ-10450232 250 mg</title>
          <description>One JNJ-10450232 250 mg capsule and two placebo capsules taken orally</description>
        </group>
        <group group_id="B4">
          <title>JNJ-10450232 1000 mg</title>
          <description>One JNJ-10450232 250 mg capsule, one JNJ-10450232 750 mg capsule, and one placebo capsule taken orally</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="67"/>
            <count group_id="B2" value="67"/>
            <count group_id="B3" value="69"/>
            <count group_id="B4" value="66"/>
            <count group_id="B5" value="269"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19.2" spread="2.69"/>
                    <measurement group_id="B2" value="19.0" spread="1.64"/>
                    <measurement group_id="B3" value="19.0" spread="2.13"/>
                    <measurement group_id="B4" value="19.3" spread="1.95"/>
                    <measurement group_id="B5" value="19.1" spread="2.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="67"/>
                    <measurement group_id="B2" value="67"/>
                    <measurement group_id="B3" value="69"/>
                    <measurement group_id="B4" value="66"/>
                    <measurement group_id="B5" value="269"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>USA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67"/>
                    <measurement group_id="B2" value="67"/>
                    <measurement group_id="B3" value="69"/>
                    <measurement group_id="B4" value="66"/>
                    <measurement group_id="B5" value="269"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Analgesic Efficacy From 0 to 6 Hours After the Dose Using the Time-weighted Sum of Pain Intensity Difference (SPID 0-6)</title>
        <description>Time-weighted sum of pain intensity difference by first multiplying each pain intensity difference (PID) score by the time from the previous time point, and adding them together for each scheduled time point within 0-6 hours. Time points included 15 minutes, 30 minutes, 45 minutes, 1 hour, 1.5 hours, 2 hours, 3 hours, 4 hours, 5 hours, and 6 hours. The minimum SPID 0-6 was -30 and the maximum SPID 0-6 was 60, where higher is better. Pain intensity is the amount of pain experienced on a scale of 1-10 (where 1=no pain and 10=very severe pain).</description>
        <time_frame>6 Hours</time_frame>
        <population>Analysis is based on the Intent-to-Treat (ITT) population, which included all subjects who were randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Three placebo capsules taken orally</description>
          </group>
          <group group_id="O2">
            <title>Acetaminophen 1000 mg</title>
            <description>Two encapsulated 500 mg tablets and one placebo capsule taken orally</description>
          </group>
          <group group_id="O3">
            <title>JNJ-10450232 250 mg</title>
            <description>One JNJ-10450232 250 mg capsule and two placebo capsules taken orally</description>
          </group>
          <group group_id="O4">
            <title>JNJ-10450232 1000 mg</title>
            <description>One JNJ-10450232 250 mg capsule, one JNJ-10450232 750 mg capsule, and one placebo capsule taken orally</description>
          </group>
        </group_list>
        <measure>
          <title>Analgesic Efficacy From 0 to 6 Hours After the Dose Using the Time-weighted Sum of Pain Intensity Difference (SPID 0-6)</title>
          <description>Time-weighted sum of pain intensity difference by first multiplying each pain intensity difference (PID) score by the time from the previous time point, and adding them together for each scheduled time point within 0-6 hours. Time points included 15 minutes, 30 minutes, 45 minutes, 1 hour, 1.5 hours, 2 hours, 3 hours, 4 hours, 5 hours, and 6 hours. The minimum SPID 0-6 was -30 and the maximum SPID 0-6 was 60, where higher is better. Pain intensity is the amount of pain experienced on a scale of 1-10 (where 1=no pain and 10=very severe pain).</description>
          <population>Analysis is based on the Intent-to-Treat (ITT) population, which included all subjects who were randomized.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="67"/>
                <count group_id="O3" value="69"/>
                <count group_id="O4" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.37" spread="1.783"/>
                    <measurement group_id="O2" value="20.75" spread="1.783"/>
                    <measurement group_id="O3" value="8.95" spread="1.757"/>
                    <measurement group_id="O4" value="20.56" spread="1.797"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>16.38</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.522</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>11.42</ci_lower_limit>
            <ci_upper_limit>21.35</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.068</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>4.58</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.503</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.35</ci_lower_limit>
            <ci_upper_limit>9.51</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>16.20</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.531</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>11.21</ci_lower_limit>
            <ci_upper_limit>21.18</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-11.81</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.503</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-16.73</ci_lower_limit>
            <ci_upper_limit>-6.88</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.941</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-0.19</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.531</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.17</ci_lower_limit>
            <ci_upper_limit>4.80</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain Intensity Difference From Baseline (PID) Scores at 15 Minutes Post Dose</title>
        <description>Pain intensity is the amount of pain experienced on a scale of 1-10 (where 1=no pain and 10=very severe pain). The PID will be derived by subtracting the pain intensity from the baseline pain intensity.</description>
        <time_frame>Baseline to 15 minutes post dose</time_frame>
        <population>Analysis is based on the Intent-to-Treat (ITT) population, which included all subjects who were randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Three placebo capsules taken orally</description>
          </group>
          <group group_id="O2">
            <title>Acetaminophen 1000 mg</title>
            <description>Two encapsulated 500 mg tablets and one placebo capsule taken orally</description>
          </group>
          <group group_id="O3">
            <title>JNJ-10450232 250 mg</title>
            <description>One JNJ-10450232 250 mg capsule and two placebo capsules taken orally</description>
          </group>
          <group group_id="O4">
            <title>JNJ-10450232 1000 mg</title>
            <description>One JNJ-10450232 250 mg capsule, one JNJ-10450232 750 mg capsule, and one placebo capsule taken orally</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Intensity Difference From Baseline (PID) Scores at 15 Minutes Post Dose</title>
          <description>Pain intensity is the amount of pain experienced on a scale of 1-10 (where 1=no pain and 10=very severe pain). The PID will be derived by subtracting the pain intensity from the baseline pain intensity.</description>
          <population>Analysis is based on the Intent-to-Treat (ITT) population, which included all subjects who were randomized.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="67"/>
                <count group_id="O3" value="69"/>
                <count group_id="O4" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.13" spread="0.11"/>
                    <measurement group_id="O2" value="0.25" spread="0.11"/>
                    <measurement group_id="O3" value="0.06" spread="0.11"/>
                    <measurement group_id="O4" value="0.21" spread="0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.448</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>0.12</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.15</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.19</ci_lower_limit>
            <ci_upper_limit>0.42</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.618</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-0.08</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.15</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.38</ci_lower_limit>
            <ci_upper_limit>0.22</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.621</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>0.08</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.15</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.23</ci_lower_limit>
            <ci_upper_limit>0.38</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.207</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-0.19</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.15</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.49</ci_lower_limit>
            <ci_upper_limit>0.11</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.794</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-0.04</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.15</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.34</ci_lower_limit>
            <ci_upper_limit>0.26</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain Intensity Difference From Baseline (PID) Scores at 30 Minutes Post Dose</title>
        <description>Pain intensity is the amount of pain experienced on a scale of 1-10 (where 1=no pain and 10=very severe pain). The PID will be derived by subtracting the pain intensity from the baseline pain intensity.</description>
        <time_frame>Baseline to 30 minutes post dose</time_frame>
        <population>Analysis is based on the Intent-to-Treat (ITT) population, which included all subjects who were randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Three placebo capsules taken orally</description>
          </group>
          <group group_id="O2">
            <title>Acetaminophen 1000 mg</title>
            <description>Two encapsulated 500 mg tablets and one placebo capsule taken orally</description>
          </group>
          <group group_id="O3">
            <title>JNJ-10450232 250 mg</title>
            <description>One JNJ-10450232 250 mg capsule and two placebo capsules taken orally</description>
          </group>
          <group group_id="O4">
            <title>JNJ-10450232 1000 mg</title>
            <description>One JNJ-10450232 250 mg capsule, one JNJ-10450232 750 mg capsule, and one placebo capsule taken orally</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Intensity Difference From Baseline (PID) Scores at 30 Minutes Post Dose</title>
          <description>Pain intensity is the amount of pain experienced on a scale of 1-10 (where 1=no pain and 10=very severe pain). The PID will be derived by subtracting the pain intensity from the baseline pain intensity.</description>
          <population>Analysis is based on the Intent-to-Treat (ITT) population, which included all subjects who were randomized.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="67"/>
                <count group_id="O3" value="69"/>
                <count group_id="O4" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.25" spread="0.19"/>
                    <measurement group_id="O2" value="1.59" spread="0.19"/>
                    <measurement group_id="O3" value="0.46" spread="0.18"/>
                    <measurement group_id="O4" value="0.71" spread="0.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>1.34</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.26</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.82</ci_lower_limit>
            <ci_upper_limit>1.86</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.420</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>0.21</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.26</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.30</ci_lower_limit>
            <ci_upper_limit>0.72</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.083</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>0.46</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.26</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.06</ci_lower_limit>
            <ci_upper_limit>0.97</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-1.13</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.26</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.64</ci_lower_limit>
            <ci_upper_limit>-0.62</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-0.88</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.26</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.40</ci_lower_limit>
            <ci_upper_limit>-0.37</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain Intensity Difference From Baseline (PID) Scores at 45 Minutes Post Dose</title>
        <description>Pain intensity is the amount of pain experienced on a scale of 1-10 (where 1=no pain and 10=very severe pain). The PID will be derived by subtracting the pain intensity from the baseline pain intensity.</description>
        <time_frame>Baseline to 45 minutes post dose</time_frame>
        <population>Analysis is based on the Intent-to-Treat (ITT) population, which included all subjects who were randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Three placebo capsules taken orally</description>
          </group>
          <group group_id="O2">
            <title>Acetaminophen 1000 mg</title>
            <description>Two encapsulated 500 mg tablets and one placebo capsule taken orally</description>
          </group>
          <group group_id="O3">
            <title>JNJ-10450232 250 mg</title>
            <description>One JNJ-10450232 250 mg capsule and two placebo capsules taken orally</description>
          </group>
          <group group_id="O4">
            <title>JNJ-10450232 1000 mg</title>
            <description>One JNJ-10450232 250 mg capsule, one JNJ-10450232 750 mg capsule, and one placebo capsule taken orally</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Intensity Difference From Baseline (PID) Scores at 45 Minutes Post Dose</title>
          <description>Pain intensity is the amount of pain experienced on a scale of 1-10 (where 1=no pain and 10=very severe pain). The PID will be derived by subtracting the pain intensity from the baseline pain intensity.</description>
          <population>Analysis is based on the Intent-to-Treat (ITT) population, which included all subjects who were randomized.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="67"/>
                <count group_id="O3" value="69"/>
                <count group_id="O4" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.28" spread="0.24"/>
                    <measurement group_id="O2" value="3.22" spread="0.24"/>
                    <measurement group_id="O3" value="0.91" spread="0.23"/>
                    <measurement group_id="O4" value="1.51" spread="0.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>2.93</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.33</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.28</ci_lower_limit>
            <ci_upper_limit>3.59</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.058</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>0.63</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.33</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.02</ci_lower_limit>
            <ci_upper_limit>1.29</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>1.23</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.34</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.57</ci_lower_limit>
            <ci_upper_limit>1.89</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-2.30</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.33</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.96</ci_lower_limit>
            <ci_upper_limit>-1.65</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-1.71</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.34</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.37</ci_lower_limit>
            <ci_upper_limit>-1.04</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain Intensity Difference From Baseline (PID) Scores at 1 Hour Post Dose</title>
        <description>Pain intensity is the amount of pain experienced on a scale of 1-10 (where 1=no pain and 10=very severe pain). The PID will be derived by subtracting the pain intensity from the baseline pain intensity.</description>
        <time_frame>Baseline to 1 hour post dose</time_frame>
        <population>Analysis is based on the Intent-to-Treat (ITT) population, which included all subjects who were randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Three placebo capsules taken orally</description>
          </group>
          <group group_id="O2">
            <title>Acetaminophen 1000 mg</title>
            <description>Two encapsulated 500 mg tablets and one placebo capsule taken orally</description>
          </group>
          <group group_id="O3">
            <title>JNJ-10450232 250 mg</title>
            <description>One JNJ-10450232 250 mg capsule and two placebo capsules taken orally</description>
          </group>
          <group group_id="O4">
            <title>JNJ-10450232 1000 mg</title>
            <description>One JNJ-10450232 250 mg capsule, one JNJ-10450232 750 mg capsule, and one placebo capsule taken orally</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Intensity Difference From Baseline (PID) Scores at 1 Hour Post Dose</title>
          <description>Pain intensity is the amount of pain experienced on a scale of 1-10 (where 1=no pain and 10=very severe pain). The PID will be derived by subtracting the pain intensity from the baseline pain intensity.</description>
          <population>Analysis is based on the Intent-to-Treat (ITT) population, which included all subjects who were randomized.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="67"/>
                <count group_id="O3" value="69"/>
                <count group_id="O4" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.25" spread="0.26"/>
                    <measurement group_id="O2" value="3.98" spread="0.26"/>
                    <measurement group_id="O3" value="1.03" spread="0.26"/>
                    <measurement group_id="O4" value="2.19" spread="0.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>3.73</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.37</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.01</ci_lower_limit>
            <ci_upper_limit>4.46</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.035</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>0.78</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.36</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.06</ci_lower_limit>
            <ci_upper_limit>1.49</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>1.94</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.37</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.21</ci_lower_limit>
            <ci_upper_limit>2.67</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-2.96</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.36</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.68</ci_lower_limit>
            <ci_upper_limit>-2.24</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-1.79</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.37</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.52</ci_lower_limit>
            <ci_upper_limit>-1.07</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain Intensity Difference From Baseline (PID) Scores at 1.5 Hours Post Dose</title>
        <description>Pain intensity is the amount of pain experienced on a scale of 1-10 (where 1=no pain and 10=very severe pain). The PID will be derived by subtracting the pain intensity from the baseline pain intensity.</description>
        <time_frame>Baseline to 1.5 hours post dose</time_frame>
        <population>Analysis is based on the Intent-to-Treat (ITT) population, which included all subjects who were randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Three placebo capsules taken orally</description>
          </group>
          <group group_id="O2">
            <title>Acetaminophen 1000 mg</title>
            <description>Two encapsulated 500 mg tablets and one placebo capsule taken orally</description>
          </group>
          <group group_id="O3">
            <title>JNJ-10450232 250 mg</title>
            <description>One JNJ-10450232 250 mg capsule and two placebo capsules taken orally</description>
          </group>
          <group group_id="O4">
            <title>JNJ-10450232 1000 mg</title>
            <description>One JNJ-10450232 250 mg capsule, one JNJ-10450232 750 mg capsule, and one placebo capsule taken orally</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Intensity Difference From Baseline (PID) Scores at 1.5 Hours Post Dose</title>
          <description>Pain intensity is the amount of pain experienced on a scale of 1-10 (where 1=no pain and 10=very severe pain). The PID will be derived by subtracting the pain intensity from the baseline pain intensity.</description>
          <population>Analysis is based on the Intent-to-Treat (ITT) population, which included all subjects who were randomized.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="67"/>
                <count group_id="O3" value="69"/>
                <count group_id="O4" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.37" spread="0.28"/>
                    <measurement group_id="O2" value="4.35" spread="0.28"/>
                    <measurement group_id="O3" value="1.23" spread="0.28"/>
                    <measurement group_id="O4" value="2.85" spread="0.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>3.99</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.39</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.21</ci_lower_limit>
            <ci_upper_limit>4.77</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.028</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>0.86</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.39</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.09</ci_lower_limit>
            <ci_upper_limit>1.64</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>2.48</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.40</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.70</ci_lower_limit>
            <ci_upper_limit>3.26</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-3.12</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.39</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.90</ci_lower_limit>
            <ci_upper_limit>-2.35</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-1.51</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.40</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.29</ci_lower_limit>
            <ci_upper_limit>-0.73</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain Intensity Difference From Baseline (PID) Scores at 2 Hours Post Dose</title>
        <description>Pain intensity is the amount of pain experienced on a scale of 1-10 (where 1=no pain and 10=very severe pain). The PID will be derived by subtracting the pain intensity from the baseline pain intensity.</description>
        <time_frame>Baseline to 2 hours post dose</time_frame>
        <population>Analysis is based on the Intent-to-Treat (ITT) population, which included all subjects who were randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Three placebo capsules taken orally</description>
          </group>
          <group group_id="O2">
            <title>Acetaminophen 1000 mg</title>
            <description>Two encapsulated 500 mg tablets and one placebo capsule taken orally</description>
          </group>
          <group group_id="O3">
            <title>JNJ-10450232 250 mg</title>
            <description>One JNJ-10450232 250 mg capsule and two placebo capsules taken orally</description>
          </group>
          <group group_id="O4">
            <title>JNJ-10450232 1000 mg</title>
            <description>One JNJ-10450232 250 mg capsule, one JNJ-10450232 750 mg capsule, and one placebo capsule taken orally</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Intensity Difference From Baseline (PID) Scores at 2 Hours Post Dose</title>
          <description>Pain intensity is the amount of pain experienced on a scale of 1-10 (where 1=no pain and 10=very severe pain). The PID will be derived by subtracting the pain intensity from the baseline pain intensity.</description>
          <population>Analysis is based on the Intent-to-Treat (ITT) population, which included all subjects who were randomized.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="67"/>
                <count group_id="O3" value="69"/>
                <count group_id="O4" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.41" spread="0.31"/>
                    <measurement group_id="O2" value="4.20" spread="0.31"/>
                    <measurement group_id="O3" value="1.43" spread="0.31"/>
                    <measurement group_id="O4" value="3.48" spread="0.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>3.78</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.44</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.92</ci_lower_limit>
            <ci_upper_limit>4.65</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.021</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>1.02</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.44</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.16</ci_lower_limit>
            <ci_upper_limit>1.88</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>3.06</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.44</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.19</ci_lower_limit>
            <ci_upper_limit>3.93</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-2.77</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.44</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.63</ci_lower_limit>
            <ci_upper_limit>-1.91</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.104</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-0.72</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.44</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.59</ci_lower_limit>
            <ci_upper_limit>0.15</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain Intensity Difference From Baseline (PID) Scores at 3 Hours Post Dose</title>
        <description>Pain intensity is the amount of pain experienced on a scale of 1-10 (where 1=no pain and 10=very severe pain). The PID will be derived by subtracting the pain intensity from the baseline pain intensity.</description>
        <time_frame>Baseline to 3 hours post dose</time_frame>
        <population>Analysis is based on the Intent-to-Treat (ITT) population, which included all subjects who were randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Three placebo capsules taken orally</description>
          </group>
          <group group_id="O2">
            <title>Acetaminophen 1000 mg</title>
            <description>Two encapsulated 500 mg tablets and one placebo capsule taken orally</description>
          </group>
          <group group_id="O3">
            <title>JNJ-10450232 250 mg</title>
            <description>One JNJ-10450232 250 mg capsule and two placebo capsules taken orally</description>
          </group>
          <group group_id="O4">
            <title>JNJ-10450232 1000 mg</title>
            <description>One JNJ-10450232 250 mg capsule, one JNJ-10450232 750 mg capsule, and one placebo capsule taken orally</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Intensity Difference From Baseline (PID) Scores at 3 Hours Post Dose</title>
          <description>Pain intensity is the amount of pain experienced on a scale of 1-10 (where 1=no pain and 10=very severe pain). The PID will be derived by subtracting the pain intensity from the baseline pain intensity.</description>
          <population>Analysis is based on the Intent-to-Treat (ITT) population, which included all subjects who were randomized.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="67"/>
                <count group_id="O3" value="69"/>
                <count group_id="O4" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.71" spread="0.34"/>
                    <measurement group_id="O2" value="3.84" spread="0.34"/>
                    <measurement group_id="O3" value="1.69" spread="0.34"/>
                    <measurement group_id="O4" value="3.86" spread="0.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>3.13</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.48</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.18</ci_lower_limit>
            <ci_upper_limit>4.07</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.041</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>0.98</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.48</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.04</ci_lower_limit>
            <ci_upper_limit>1.92</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>3.14</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.48</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.19</ci_lower_limit>
            <ci_upper_limit>4.09</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-2.15</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.48</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.09</ci_lower_limit>
            <ci_upper_limit>-1.21</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.973</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>0.02</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.48</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.93</ci_lower_limit>
            <ci_upper_limit>0.97</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain Intensity Difference From Baseline (PID) Scores at 4 Hours Post Dose</title>
        <description>Pain intensity is the amount of pain experienced on a scale of 1-10 (where 1=no pain and 10=very severe pain). The PID will be derived by subtracting the pain intensity from the baseline pain intensity.</description>
        <time_frame>Baseline to 4 hours post dose</time_frame>
        <population>Analysis is based on the Intent-to-Treat (ITT) population, which included all subjects who were randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Three placebo capsules taken orally</description>
          </group>
          <group group_id="O2">
            <title>Acetaminophen 1000 mg</title>
            <description>Two encapsulated 500 mg tablets and one placebo capsule taken orally</description>
          </group>
          <group group_id="O3">
            <title>JNJ-10450232 250 mg</title>
            <description>One JNJ-10450232 250 mg capsule and two placebo capsules taken orally</description>
          </group>
          <group group_id="O4">
            <title>JNJ-10450232 1000 mg</title>
            <description>One JNJ-10450232 250 mg capsule, one JNJ-10450232 750 mg capsule, and one placebo capsule taken orally</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Intensity Difference From Baseline (PID) Scores at 4 Hours Post Dose</title>
          <description>Pain intensity is the amount of pain experienced on a scale of 1-10 (where 1=no pain and 10=very severe pain). The PID will be derived by subtracting the pain intensity from the baseline pain intensity.</description>
          <population>Analysis is based on the Intent-to-Treat (ITT) population, which included all subjects who were randomized.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="67"/>
                <count group_id="O3" value="69"/>
                <count group_id="O4" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.91" spread="0.36"/>
                    <measurement group_id="O2" value="3.78" spread="0.36"/>
                    <measurement group_id="O3" value="1.79" spread="0.35"/>
                    <measurement group_id="O4" value="4.17" spread="0.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>2.87</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.51</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.87</ci_lower_limit>
            <ci_upper_limit>3.87</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.079</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>0.89</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.50</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.10</ci_lower_limit>
            <ci_upper_limit>1.88</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>3.27</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.51</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.27</ci_lower_limit>
            <ci_upper_limit>4.27</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-1.99</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.50</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.98</ci_lower_limit>
            <ci_upper_limit>-1.00</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.440</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>0.39</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.51</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.61</ci_lower_limit>
            <ci_upper_limit>1.40</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain Intensity Difference From Baseline (PID) Scores at 5 Hours Post Dose</title>
        <description>Pain intensity is the amount of pain experienced on a scale of 1-10 (where 1=no pain and 10=very severe pain). The PID will be derived by subtracting the pain intensity from the baseline pain intensity.</description>
        <time_frame>Baseline to 5 hours post dose</time_frame>
        <population>Analysis is based on the Intent-to-Treat (ITT) population, which included all subjects who were randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Three placebo capsules taken orally</description>
          </group>
          <group group_id="O2">
            <title>Acetaminophen 1000 mg</title>
            <description>Two encapsulated 500 mg tablets and one placebo capsule taken orally</description>
          </group>
          <group group_id="O3">
            <title>JNJ-10450232 250 mg</title>
            <description>One JNJ-10450232 250 mg capsule and two placebo capsules taken orally</description>
          </group>
          <group group_id="O4">
            <title>JNJ-10450232 1000 mg</title>
            <description>One JNJ-10450232 250 mg capsule, one JNJ-10450232 750 mg capsule, and one placebo capsule taken orally</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Intensity Difference From Baseline (PID) Scores at 5 Hours Post Dose</title>
          <description>Pain intensity is the amount of pain experienced on a scale of 1-10 (where 1=no pain and 10=very severe pain). The PID will be derived by subtracting the pain intensity from the baseline pain intensity.</description>
          <population>Analysis is based on the Intent-to-Treat (ITT) population, which included all subjects who were randomized.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="67"/>
                <count group_id="O3" value="69"/>
                <count group_id="O4" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.01" spread="0.37"/>
                    <measurement group_id="O2" value="3.56" spread="0.37"/>
                    <measurement group_id="O3" value="1.82" spread="0.36"/>
                    <measurement group_id="O4" value="4.14" spread="0.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>2.55</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.52</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.52</ci_lower_limit>
            <ci_upper_limit>3.57</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.118</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>0.81</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.52</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.21</ci_lower_limit>
            <ci_upper_limit>1.83</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>3.13</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.52</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.10</ci_lower_limit>
            <ci_upper_limit>4.16</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-1.73</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.52</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.75</ci_lower_limit>
            <ci_upper_limit>-0.71</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.262</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>0.59</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.52</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.44</ci_lower_limit>
            <ci_upper_limit>1.62</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain Intensity Difference From Baseline (PID) Scores at 6 Hours Post Dose</title>
        <description>Pain intensity is the amount of pain experienced on a scale of 1-10 (where 1=no pain and 10=very severe pain). The PID will be derived by subtracting the pain intensity from the baseline pain intensity.</description>
        <time_frame>Baseline to 6 hours post dose</time_frame>
        <population>Analysis is based on the Intent-to-Treat (ITT) population, which included all subjects who were randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Three placebo capsules taken orally</description>
          </group>
          <group group_id="O2">
            <title>Acetaminophen 1000 mg</title>
            <description>Two encapsulated 500 mg tablets and one placebo capsule taken orally</description>
          </group>
          <group group_id="O3">
            <title>JNJ-10450232 250 mg</title>
            <description>One JNJ-10450232 250 mg capsule and two placebo capsules taken orally</description>
          </group>
          <group group_id="O4">
            <title>JNJ-10450232 1000 mg</title>
            <description>One JNJ-10450232 250 mg capsule, one JNJ-10450232 750 mg capsule, and one placebo capsule taken orally</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Intensity Difference From Baseline (PID) Scores at 6 Hours Post Dose</title>
          <description>Pain intensity is the amount of pain experienced on a scale of 1-10 (where 1=no pain and 10=very severe pain). The PID will be derived by subtracting the pain intensity from the baseline pain intensity.</description>
          <population>Analysis is based on the Intent-to-Treat (ITT) population, which included all subjects who were randomized.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="67"/>
                <count group_id="O3" value="69"/>
                <count group_id="O4" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.12" spread="0.37"/>
                    <measurement group_id="O2" value="3.04" spread="0.37"/>
                    <measurement group_id="O3" value="1.69" spread="0.37"/>
                    <measurement group_id="O4" value="4.07" spread="0.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>1.92</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.53</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.88</ci_lower_limit>
            <ci_upper_limit>2.96</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.271</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>0.58</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.52</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.45</ci_lower_limit>
            <ci_upper_limit>1.61</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>2.95</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.53</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.91</ci_lower_limit>
            <ci_upper_limit>3.99</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.011</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-1.34</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.52</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.37</ci_lower_limit>
            <ci_upper_limit>-0.32</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.052</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>1.03</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.53</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.01</ci_lower_limit>
            <ci_upper_limit>2.07</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain Intensity Difference From Baseline (PID) Scores at 7 Hours Post Dose</title>
        <description>Pain intensity is the amount of pain experienced on a scale of 1-10 (where 1=no pain and 10=very severe pain). The PID will be derived by subtracting the pain intensity from the baseline pain intensity.</description>
        <time_frame>Baseline to 7 hours post dose</time_frame>
        <population>Analysis is based on the Intent-to-Treat (ITT) population, which included all subjects who were randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Three placebo capsules taken orally</description>
          </group>
          <group group_id="O2">
            <title>Acetaminophen 1000 mg</title>
            <description>Two encapsulated 500 mg tablets and one placebo capsule taken orally</description>
          </group>
          <group group_id="O3">
            <title>JNJ-10450232 250 mg</title>
            <description>One JNJ-10450232 250 mg capsule and two placebo capsules taken orally</description>
          </group>
          <group group_id="O4">
            <title>JNJ-10450232 1000 mg</title>
            <description>One JNJ-10450232 250 mg capsule, one JNJ-10450232 750 mg capsule, and one placebo capsule taken orally</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Intensity Difference From Baseline (PID) Scores at 7 Hours Post Dose</title>
          <description>Pain intensity is the amount of pain experienced on a scale of 1-10 (where 1=no pain and 10=very severe pain). The PID will be derived by subtracting the pain intensity from the baseline pain intensity.</description>
          <population>Analysis is based on the Intent-to-Treat (ITT) population, which included all subjects who were randomized.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="67"/>
                <count group_id="O3" value="69"/>
                <count group_id="O4" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.13" spread="0.37"/>
                    <measurement group_id="O2" value="2.38" spread="0.37"/>
                    <measurement group_id="O3" value="1.66" spread="0.37"/>
                    <measurement group_id="O4" value="3.94" spread="0.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.018</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>1.25</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.53</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.21</ci_lower_limit>
            <ci_upper_limit>2.29</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.310</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>0.53</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.52</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.50</ci_lower_limit>
            <ci_upper_limit>1.56</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>2.80</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.53</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.76</ci_lower_limit>
            <ci_upper_limit>3.85</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.172</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-0.72</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.52</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.75</ci_lower_limit>
            <ci_upper_limit>0.31</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.004</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>1.55</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.53</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.51</ci_lower_limit>
            <ci_upper_limit>2.60</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain Intensity Difference From Baseline (PID) Scores at 8 Hours Post Dose</title>
        <description>Pain intensity is the amount of pain experienced on a scale of 1-10 (where 1=no pain and 10=very severe pain). The PID will be derived by subtracting the pain intensity from the baseline pain intensity.</description>
        <time_frame>Baseline to 8 hours post dose</time_frame>
        <population>Analysis is based on the Intent-to-Treat (ITT) population, which included all subjects who were randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Three placebo capsules taken orally</description>
          </group>
          <group group_id="O2">
            <title>Acetaminophen 1000 mg</title>
            <description>Two encapsulated 500 mg tablets and one placebo capsule taken orally</description>
          </group>
          <group group_id="O3">
            <title>JNJ-10450232 250 mg</title>
            <description>One JNJ-10450232 250 mg capsule and two placebo capsules taken orally</description>
          </group>
          <group group_id="O4">
            <title>JNJ-10450232 1000 mg</title>
            <description>One JNJ-10450232 250 mg capsule, one JNJ-10450232 750 mg capsule, and one placebo capsule taken orally</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Intensity Difference From Baseline (PID) Scores at 8 Hours Post Dose</title>
          <description>Pain intensity is the amount of pain experienced on a scale of 1-10 (where 1=no pain and 10=very severe pain). The PID will be derived by subtracting the pain intensity from the baseline pain intensity.</description>
          <population>Analysis is based on the Intent-to-Treat (ITT) population, which included all subjects who were randomized.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="67"/>
                <count group_id="O3" value="69"/>
                <count group_id="O4" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.15" spread="0.36"/>
                    <measurement group_id="O2" value="1.99" spread="0.36"/>
                    <measurement group_id="O3" value="1.51" spread="0.35"/>
                    <measurement group_id="O4" value="4.00" spread="0.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.102</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>0.84</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.51</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.17</ci_lower_limit>
            <ci_upper_limit>1.84</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.479</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>0.36</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.51</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.64</ci_lower_limit>
            <ci_upper_limit>1.35</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>2.85</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.51</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.85</ci_lower_limit>
            <ci_upper_limit>3.86</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.345</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-0.48</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.51</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.47</ci_lower_limit>
            <ci_upper_limit>0.52</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>2.01</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.51</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.01</ci_lower_limit>
            <ci_upper_limit>3.02</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain Intensity Difference From Baseline (PID) Scores at 9 Hours Post Dose</title>
        <description>Pain intensity is the amount of pain experienced on a scale of 1-10 (where 1=no pain and 10=very severe pain). The PID will be derived by subtracting the pain intensity from the baseline pain intensity.</description>
        <time_frame>Baseline to 9 hours post dose</time_frame>
        <population>Analysis is based on the Intent-to-Treat (ITT) population, which included all subjects who were randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Three placebo capsules taken orally</description>
          </group>
          <group group_id="O2">
            <title>Acetaminophen 1000 mg</title>
            <description>Two encapsulated 500 mg tablets and one placebo capsule taken orally</description>
          </group>
          <group group_id="O3">
            <title>JNJ-10450232 250 mg</title>
            <description>One JNJ-10450232 250 mg capsule and two placebo capsules taken orally</description>
          </group>
          <group group_id="O4">
            <title>JNJ-10450232 1000 mg</title>
            <description>One JNJ-10450232 250 mg capsule, one JNJ-10450232 750 mg capsule, and one placebo capsule taken orally</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Intensity Difference From Baseline (PID) Scores at 9 Hours Post Dose</title>
          <description>Pain intensity is the amount of pain experienced on a scale of 1-10 (where 1=no pain and 10=very severe pain). The PID will be derived by subtracting the pain intensity from the baseline pain intensity.</description>
          <population>Analysis is based on the Intent-to-Treat (ITT) population, which included all subjects who were randomized.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="67"/>
                <count group_id="O3" value="69"/>
                <count group_id="O4" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.19" spread="0.36"/>
                    <measurement group_id="O2" value="1.69" spread="0.36"/>
                    <measurement group_id="O3" value="1.73" spread="0.36"/>
                    <measurement group_id="O4" value="3.91" spread="0.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.338</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>0.49</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.51</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.52</ci_lower_limit>
            <ci_upper_limit>1.51</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.299</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>0.53</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.51</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.47</ci_lower_limit>
            <ci_upper_limit>1.54</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>2.72</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.52</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.70</ci_lower_limit>
            <ci_upper_limit>3.73</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.942</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>0.04</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.51</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.97</ci_lower_limit>
            <ci_upper_limit>1.04</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>2.22</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.52</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.21</ci_lower_limit>
            <ci_upper_limit>3.24</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain Intensity Difference From Baseline (PID) Scores at 10 Hours Post Dose</title>
        <description>Pain intensity is the amount of pain experienced on a scale of 1-10 (where 1=no pain and 10=very severe pain). The PID will be derived by subtracting the pain intensity from the baseline pain intensity.</description>
        <time_frame>Baseline to 10 hours post dose</time_frame>
        <population>Analysis is based on the Intent-to-Treat (ITT) population, which included all subjects who were randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Three placebo capsules taken orally</description>
          </group>
          <group group_id="O2">
            <title>Acetaminophen 1000 mg</title>
            <description>Two encapsulated 500 mg tablets and one placebo capsule taken orally</description>
          </group>
          <group group_id="O3">
            <title>JNJ-10450232 250 mg</title>
            <description>One JNJ-10450232 250 mg capsule and two placebo capsules taken orally</description>
          </group>
          <group group_id="O4">
            <title>JNJ-10450232 1000 mg</title>
            <description>One JNJ-10450232 250 mg capsule, one JNJ-10450232 750 mg capsule, and one placebo capsule taken orally</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Intensity Difference From Baseline (PID) Scores at 10 Hours Post Dose</title>
          <description>Pain intensity is the amount of pain experienced on a scale of 1-10 (where 1=no pain and 10=very severe pain). The PID will be derived by subtracting the pain intensity from the baseline pain intensity.</description>
          <population>Analysis is based on the Intent-to-Treat (ITT) population, which included all subjects who were randomized.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="67"/>
                <count group_id="O3" value="69"/>
                <count group_id="O4" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.08" spread="0.36"/>
                    <measurement group_id="O2" value="1.60" spread="0.36"/>
                    <measurement group_id="O3" value="1.57" spread="0.36"/>
                    <measurement group_id="O4" value="3.87" spread="0.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.306</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>0.52</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.51</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.48</ci_lower_limit>
            <ci_upper_limit>1.53</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.335</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>0.49</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.51</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.51</ci_lower_limit>
            <ci_upper_limit>1.49</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>2.79</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.51</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.78</ci_lower_limit>
            <ci_upper_limit>3.80</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.946</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-0.03</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.51</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.03</ci_lower_limit>
            <ci_upper_limit>0.97</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>2.27</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.51</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.25</ci_lower_limit>
            <ci_upper_limit>3.28</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain Intensity Difference From Baseline (PID) Scores at 11 Hours Post Dose</title>
        <description>Pain intensity is the amount of pain experienced on a scale of 1-10 (where 1=no pain and 10=very severe pain). The PID will be derived by subtracting the pain intensity from the baseline pain intensity.</description>
        <time_frame>Baseline to 11 hours post dose</time_frame>
        <population>Analysis is based on the Intent-to-Treat (ITT) population, which included all subjects who were randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Three placebo capsules taken orally</description>
          </group>
          <group group_id="O2">
            <title>Acetaminophen 1000 mg</title>
            <description>Two encapsulated 500 mg tablets and one placebo capsule taken orally</description>
          </group>
          <group group_id="O3">
            <title>JNJ-10450232 250 mg</title>
            <description>One JNJ-10450232 250 mg capsule and two placebo capsules taken orally</description>
          </group>
          <group group_id="O4">
            <title>JNJ-10450232 1000 mg</title>
            <description>One JNJ-10450232 250 mg capsule, one JNJ-10450232 750 mg capsule, and one placebo capsule taken orally</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Intensity Difference From Baseline (PID) Scores at 11 Hours Post Dose</title>
          <description>Pain intensity is the amount of pain experienced on a scale of 1-10 (where 1=no pain and 10=very severe pain). The PID will be derived by subtracting the pain intensity from the baseline pain intensity.</description>
          <population>Analysis is based on the Intent-to-Treat (ITT) population, which included all subjects who were randomized.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="67"/>
                <count group_id="O3" value="69"/>
                <count group_id="O4" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.03" spread="0.36"/>
                    <measurement group_id="O2" value="1.58" spread="0.36"/>
                    <measurement group_id="O3" value="1.57" spread="0.36"/>
                    <measurement group_id="O4" value="3.70" spread="0.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.279</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>0.55</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.51</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.45</ci_lower_limit>
            <ci_upper_limit>1.56</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.292</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>0.54</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.51</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.46</ci_lower_limit>
            <ci_upper_limit>1.53</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>2.67</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.51</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.66</ci_lower_limit>
            <ci_upper_limit>3.68</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.971</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-0.02</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.51</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.02</ci_lower_limit>
            <ci_upper_limit>0.98</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>2.11</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.51</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.11</ci_lower_limit>
            <ci_upper_limit>3.12</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain Intensity Difference From Baseline (PID) Scores at 12 Hours Post Dose</title>
        <description>Pain intensity is the amount of pain experienced on a scale of 1-10 (where 1=no pain and 10=very severe pain). The PID will be derived by subtracting the pain intensity from the baseline pain intensity.</description>
        <time_frame>Baseline to 12 hours post dose</time_frame>
        <population>Analysis is based on the Intent-to-Treat (ITT) population, which included all subjects who were randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Three placebo capsules taken orally</description>
          </group>
          <group group_id="O2">
            <title>Acetaminophen 1000 mg</title>
            <description>Two encapsulated 500 mg tablets and one placebo capsule taken orally</description>
          </group>
          <group group_id="O3">
            <title>JNJ-10450232 250 mg</title>
            <description>One JNJ-10450232 250 mg capsule and two placebo capsules taken orally</description>
          </group>
          <group group_id="O4">
            <title>JNJ-10450232 1000 mg</title>
            <description>One JNJ-10450232 250 mg capsule, one JNJ-10450232 750 mg capsule, and one placebo capsule taken orally</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Intensity Difference From Baseline (PID) Scores at 12 Hours Post Dose</title>
          <description>Pain intensity is the amount of pain experienced on a scale of 1-10 (where 1=no pain and 10=very severe pain). The PID will be derived by subtracting the pain intensity from the baseline pain intensity.</description>
          <population>Analysis is based on the Intent-to-Treat (ITT) population, which included all subjects who were randomized.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="67"/>
                <count group_id="O3" value="69"/>
                <count group_id="O4" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.08" spread="0.36"/>
                    <measurement group_id="O2" value="1.57" spread="0.36"/>
                    <measurement group_id="O3" value="1.39" spread="0.35"/>
                    <measurement group_id="O4" value="3.61" spread="0.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.329</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>0.50</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.51</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.50</ci_lower_limit>
            <ci_upper_limit>1.50</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.531</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>0.32</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.50</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.68</ci_lower_limit>
            <ci_upper_limit>1.31</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>2.53</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.51</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.53</ci_lower_limit>
            <ci_upper_limit>3.54</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.722</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-0.18</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.50</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.17</ci_lower_limit>
            <ci_upper_limit>0.81</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>2.04</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.51</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.03</ci_lower_limit>
            <ci_upper_limit>3.04</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain Intensity Difference From Baseline (PID) Scores at 16 Hours Post Dose</title>
        <description>Pain intensity is the amount of pain experienced on a scale of 1-10 (where 1=no pain and 10=very severe pain). The PID will be derived by subtracting the pain intensity from the baseline pain intensity.</description>
        <time_frame>Baseline to 16 hours post dose</time_frame>
        <population>Analysis is based on the Intent-to-Treat (ITT) population, which included all subjects who were randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Three placebo capsules taken orally</description>
          </group>
          <group group_id="O2">
            <title>Acetaminophen 1000 mg</title>
            <description>Two encapsulated 500 mg tablets and one placebo capsule taken orally</description>
          </group>
          <group group_id="O3">
            <title>JNJ-10450232 250 mg</title>
            <description>One JNJ-10450232 250 mg capsule and two placebo capsules taken orally</description>
          </group>
          <group group_id="O4">
            <title>JNJ-10450232 1000 mg</title>
            <description>One JNJ-10450232 250 mg capsule, one JNJ-10450232 750 mg capsule, and one placebo capsule taken orally</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Intensity Difference From Baseline (PID) Scores at 16 Hours Post Dose</title>
          <description>Pain intensity is the amount of pain experienced on a scale of 1-10 (where 1=no pain and 10=very severe pain). The PID will be derived by subtracting the pain intensity from the baseline pain intensity.</description>
          <population>Analysis is based on the Intent-to-Treat (ITT) population, which included all subjects who were randomized.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="67"/>
                <count group_id="O3" value="69"/>
                <count group_id="O4" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.93" spread="0.35"/>
                    <measurement group_id="O2" value="1.37" spread="0.35"/>
                    <measurement group_id="O3" value="1.08" spread="0.35"/>
                    <measurement group_id="O4" value="3.43" spread="0.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.380</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>0.44</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.50</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.54</ci_lower_limit>
            <ci_upper_limit>1.42</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.767</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>0.15</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.49</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.83</ci_lower_limit>
            <ci_upper_limit>1.12</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>2.50</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.50</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.52</ci_lower_limit>
            <ci_upper_limit>3.49</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.557</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-0.29</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.49</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.27</ci_lower_limit>
            <ci_upper_limit>0.68</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>2.06</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.50</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.08</ci_lower_limit>
            <ci_upper_limit>3.05</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain Intensity Difference From Baseline (PID) Scores at 24 Hours Post Dose</title>
        <description>Pain intensity is the amount of pain experienced on a scale of 1-10 (where 1=no pain and 10=very severe pain). The PID will be derived by subtracting the pain intensity from the baseline pain intensity.</description>
        <time_frame>Baseline to 24 hours post dose</time_frame>
        <population>Analysis is based on the Intent-to-Treat (ITT) population, which included all subjects who were randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Three placebo capsules taken orally</description>
          </group>
          <group group_id="O2">
            <title>Acetaminophen 1000 mg</title>
            <description>Two encapsulated 500 mg tablets and one placebo capsule taken orally</description>
          </group>
          <group group_id="O3">
            <title>JNJ-10450232 250 mg</title>
            <description>One JNJ-10450232 250 mg capsule and two placebo capsules taken orally</description>
          </group>
          <group group_id="O4">
            <title>JNJ-10450232 1000 mg</title>
            <description>One JNJ-10450232 250 mg capsule, one JNJ-10450232 750 mg capsule, and one placebo capsule taken orally</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Intensity Difference From Baseline (PID) Scores at 24 Hours Post Dose</title>
          <description>Pain intensity is the amount of pain experienced on a scale of 1-10 (where 1=no pain and 10=very severe pain). The PID will be derived by subtracting the pain intensity from the baseline pain intensity.</description>
          <population>Analysis is based on the Intent-to-Treat (ITT) population, which included all subjects who were randomized.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="67"/>
                <count group_id="O3" value="69"/>
                <count group_id="O4" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.15" spread="0.39"/>
                    <measurement group_id="O2" value="1.41" spread="0.39"/>
                    <measurement group_id="O3" value="1.29" spread="0.38"/>
                    <measurement group_id="O4" value="3.47" spread="0.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.640</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>0.26</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.55</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.83</ci_lower_limit>
            <ci_upper_limit>1.35</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.798</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>0.14</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.55</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.94</ci_lower_limit>
            <ci_upper_limit>1.22</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>2.32</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.55</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.23</ci_lower_limit>
            <ci_upper_limit>3.42</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.829</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-0.12</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.55</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.20</ci_lower_limit>
            <ci_upper_limit>0.96</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>2.06</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.55</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.97</ci_lower_limit>
            <ci_upper_limit>3.16</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain Relief (PAR) Scores at 15 Minutes Post Dose</title>
        <description>Pain relief is the amount of pain relief on a scale of 1-10 (where 1=no relief and 10=complete relief).</description>
        <time_frame>15 minutes post dose</time_frame>
        <population>Analysis is based on the Intent-to-Treat (ITT) population, which included all subjects who were randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Three placebo capsules taken orally</description>
          </group>
          <group group_id="O2">
            <title>Acetaminophen 1000 mg</title>
            <description>Two encapsulated 500 mg tablets and one placebo capsule taken orally</description>
          </group>
          <group group_id="O3">
            <title>JNJ-10450232 250 mg</title>
            <description>One JNJ-10450232 250 mg capsule and two placebo capsules taken orally</description>
          </group>
          <group group_id="O4">
            <title>JNJ-10450232 1000 mg</title>
            <description>One JNJ-10450232 250 mg capsule, one JNJ-10450232 750 mg capsule, and one placebo capsule taken orally</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Relief (PAR) Scores at 15 Minutes Post Dose</title>
          <description>Pain relief is the amount of pain relief on a scale of 1-10 (where 1=no relief and 10=complete relief).</description>
          <population>Analysis is based on the Intent-to-Treat (ITT) population, which included all subjects who were randomized.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="67"/>
                <count group_id="O3" value="69"/>
                <count group_id="O4" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.27" spread="0.11"/>
                    <measurement group_id="O2" value="0.52" spread="0.11"/>
                    <measurement group_id="O3" value="0.33" spread="0.11"/>
                    <measurement group_id="O4" value="0.38" spread="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.117</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>0.25</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.16</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.06</ci_lower_limit>
            <ci_upper_limit>0.57</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.687</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>0.06</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.16</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.25</ci_lower_limit>
            <ci_upper_limit>0.38</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.497</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>0.11</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.16</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.21</ci_lower_limit>
            <ci_upper_limit>0.43</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.239</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-0.19</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.16</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.51</ci_lower_limit>
            <ci_upper_limit>0.13</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.376</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-0.14</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.16</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.46</ci_lower_limit>
            <ci_upper_limit>0.18</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain Relief (PAR) Scores at 30 Minutes Post Dose</title>
        <description>Pain relief is the amount of pain relief on a scale of 1-10 (where 1=no relief and 10=complete relief).</description>
        <time_frame>30 minutes post dose</time_frame>
        <population>Analysis is based on the Intent-to-Treat (ITT) population, which included all subjects who were randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Three placebo capsules taken orally</description>
          </group>
          <group group_id="O2">
            <title>Acetaminophen 1000 mg</title>
            <description>Two encapsulated 500 mg tablets and one placebo capsule taken orally</description>
          </group>
          <group group_id="O3">
            <title>JNJ-10450232 250 mg</title>
            <description>One JNJ-10450232 250 mg capsule and two placebo capsules taken orally</description>
          </group>
          <group group_id="O4">
            <title>JNJ-10450232 1000 mg</title>
            <description>One JNJ-10450232 250 mg capsule, one JNJ-10450232 750 mg capsule, and one placebo capsule taken orally</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Relief (PAR) Scores at 30 Minutes Post Dose</title>
          <description>Pain relief is the amount of pain relief on a scale of 1-10 (where 1=no relief and 10=complete relief).</description>
          <population>Analysis is based on the Intent-to-Treat (ITT) population, which included all subjects who were randomized.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="67"/>
                <count group_id="O3" value="69"/>
                <count group_id="O4" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.60" spread="0.23"/>
                    <measurement group_id="O2" value="2.38" spread="0.23"/>
                    <measurement group_id="O3" value="0.90" spread="0.23"/>
                    <measurement group_id="O4" value="1.03" spread="0.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>1.78</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.32</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.14</ci_lower_limit>
            <ci_upper_limit>2.42</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.350</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>0.30</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.32</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.33</ci_lower_limit>
            <ci_upper_limit>0.94</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.183</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>0.43</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.33</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.21</ci_lower_limit>
            <ci_upper_limit>1.08</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-1.48</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.32</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.11</ci_lower_limit>
            <ci_upper_limit>-0.84</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-1.34</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.33</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.98</ci_lower_limit>
            <ci_upper_limit>-0.70</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain Relief (PAR) Scores at 45 Minutes Post Dose</title>
        <description>Pain relief is the amount of pain relief on a scale of 1-10 (where 1=no relief and 10=complete relief).</description>
        <time_frame>45 minutes post dose</time_frame>
        <population>Analysis is based on the Intent-to-Treat (ITT) population, which included all subjects who were randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Three placebo capsules taken orally</description>
          </group>
          <group group_id="O2">
            <title>Acetaminophen 1000 mg</title>
            <description>Two encapsulated 500 mg tablets and one placebo capsule taken orally</description>
          </group>
          <group group_id="O3">
            <title>JNJ-10450232 250 mg</title>
            <description>One JNJ-10450232 250 mg capsule and two placebo capsules taken orally</description>
          </group>
          <group group_id="O4">
            <title>JNJ-10450232 1000 mg</title>
            <description>One JNJ-10450232 250 mg capsule, one JNJ-10450232 750 mg capsule, and one placebo capsule taken orally</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Relief (PAR) Scores at 45 Minutes Post Dose</title>
          <description>Pain relief is the amount of pain relief on a scale of 1-10 (where 1=no relief and 10=complete relief).</description>
          <population>Analysis is based on the Intent-to-Treat (ITT) population, which included all subjects who were randomized.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="67"/>
                <count group_id="O3" value="69"/>
                <count group_id="O4" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.64" spread="0.30"/>
                    <measurement group_id="O2" value="4.42" spread="0.30"/>
                    <measurement group_id="O3" value="1.52" spread="0.30"/>
                    <measurement group_id="O4" value="2.11" spread="0.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>3.78</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.42</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.94</ci_lower_limit>
            <ci_upper_limit>4.61</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.037</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>0.88</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.42</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.05</ci_lower_limit>
            <ci_upper_limit>1.71</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>1.47</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.43</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.63</ci_lower_limit>
            <ci_upper_limit>2.30</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-2.90</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.42</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.73</ci_lower_limit>
            <ci_upper_limit>-2.07</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-2.31</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.43</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.15</ci_lower_limit>
            <ci_upper_limit>-1.47</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain Relief (PAR) Scores at 1 Hour Post Dose</title>
        <description>Pain relief is the amount of pain relief on a scale of 1-10 (where 1=no relief and 10=complete relief).</description>
        <time_frame>1 hour post dose</time_frame>
        <population>Analysis is based on the Intent-to-Treat (ITT) population, which included all subjects who were randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Three placebo capsules taken orally</description>
          </group>
          <group group_id="O2">
            <title>Acetaminophen 1000 mg</title>
            <description>Two encapsulated 500 mg tablets and one placebo capsule taken orally</description>
          </group>
          <group group_id="O3">
            <title>JNJ-10450232 250 mg</title>
            <description>One JNJ-10450232 250 mg capsule and two placebo capsules taken orally</description>
          </group>
          <group group_id="O4">
            <title>JNJ-10450232 1000 mg</title>
            <description>One JNJ-10450232 250 mg capsule, one JNJ-10450232 750 mg capsule, and one placebo capsule taken orally</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Relief (PAR) Scores at 1 Hour Post Dose</title>
          <description>Pain relief is the amount of pain relief on a scale of 1-10 (where 1=no relief and 10=complete relief).</description>
          <population>Analysis is based on the Intent-to-Treat (ITT) population, which included all subjects who were randomized.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="67"/>
                <count group_id="O3" value="69"/>
                <count group_id="O4" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.84" spread="0.33"/>
                    <measurement group_id="O2" value="5.18" spread="0.33"/>
                    <measurement group_id="O3" value="1.68" spread="0.32"/>
                    <measurement group_id="O4" value="3.09" spread="0.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>4.34</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.46</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.43</ci_lower_limit>
            <ci_upper_limit>5.25</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.067</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>0.85</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.46</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.06</ci_lower_limit>
            <ci_upper_limit>1.75</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>2.26</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.46</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.34</ci_lower_limit>
            <ci_upper_limit>3.17</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-3.49</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.46</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.40</ci_lower_limit>
            <ci_upper_limit>-2.59</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-2.08</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.46</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.00</ci_lower_limit>
            <ci_upper_limit>-1.17</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain Relief (PAR) Scores at 1.5 Hours Post Dose</title>
        <description>Pain relief is the amount of pain relief on a scale of 1-10 (where 1=no relief and 10=complete relief).</description>
        <time_frame>1.5 hours post dose</time_frame>
        <population>Analysis is based on the Intent-to-Treat (ITT) population, which included all subjects who were randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Three placebo capsules taken orally</description>
          </group>
          <group group_id="O2">
            <title>Acetaminophen 1000 mg</title>
            <description>Two encapsulated 500 mg tablets and one placebo capsule taken orally</description>
          </group>
          <group group_id="O3">
            <title>JNJ-10450232 250 mg</title>
            <description>One JNJ-10450232 250 mg capsule and two placebo capsules taken orally</description>
          </group>
          <group group_id="O4">
            <title>JNJ-10450232 1000 mg</title>
            <description>One JNJ-10450232 250 mg capsule, one JNJ-10450232 750 mg capsule, and one placebo capsule taken orally</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Relief (PAR) Scores at 1.5 Hours Post Dose</title>
          <description>Pain relief is the amount of pain relief on a scale of 1-10 (where 1=no relief and 10=complete relief).</description>
          <population>Analysis is based on the Intent-to-Treat (ITT) population, which included all subjects who were randomized.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="67"/>
                <count group_id="O3" value="69"/>
                <count group_id="O4" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.01" spread="0.35"/>
                    <measurement group_id="O2" value="5.88" spread="0.35"/>
                    <measurement group_id="O3" value="2.13" spread="0.34"/>
                    <measurement group_id="O4" value="3.97" spread="0.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>4.87</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.49</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.90</ci_lower_limit>
            <ci_upper_limit>5.84</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.023</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>1.13</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.49</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.16</ci_lower_limit>
            <ci_upper_limit>2.09</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>2.96</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.50</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.98</ci_lower_limit>
            <ci_upper_limit>3.93</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-3.75</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.49</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.71</ci_lower_limit>
            <ci_upper_limit>-2.78</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-1.91</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.50</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.89</ci_lower_limit>
            <ci_upper_limit>-0.94</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain Relief (PAR) Scores at 2 Hours Post Dose</title>
        <description>Pain relief is the amount of pain relief on a scale of 1-10 (where 1=no relief and 10=complete relief).</description>
        <time_frame>2 hours post dose</time_frame>
        <population>Analysis is based on the Intent-to-Treat (ITT) population, which included all subjects who were randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Three placebo capsules taken orally</description>
          </group>
          <group group_id="O2">
            <title>Acetaminophen 1000 mg</title>
            <description>Two encapsulated 500 mg tablets and one placebo capsule taken orally</description>
          </group>
          <group group_id="O3">
            <title>JNJ-10450232 250 mg</title>
            <description>One JNJ-10450232 250 mg capsule and two placebo capsules taken orally</description>
          </group>
          <group group_id="O4">
            <title>JNJ-10450232 1000 mg</title>
            <description>One JNJ-10450232 250 mg capsule, one JNJ-10450232 750 mg capsule, and one placebo capsule taken orally</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Relief (PAR) Scores at 2 Hours Post Dose</title>
          <description>Pain relief is the amount of pain relief on a scale of 1-10 (where 1=no relief and 10=complete relief).</description>
          <population>Analysis is based on the Intent-to-Treat (ITT) population, which included all subjects who were randomized.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="67"/>
                <count group_id="O3" value="69"/>
                <count group_id="O4" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.17" spread="0.38"/>
                    <measurement group_id="O2" value="5.88" spread="0.38"/>
                    <measurement group_id="O3" value="2.53" spread="0.38"/>
                    <measurement group_id="O4" value="4.90" spread="0.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>4.71</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.54</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.64</ci_lower_limit>
            <ci_upper_limit>5.78</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.012</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>1.36</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.54</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.30</ci_lower_limit>
            <ci_upper_limit>2.42</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>3.73</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.54</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.66</ci_lower_limit>
            <ci_upper_limit>4.81</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-3.35</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.54</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.41</ci_lower_limit>
            <ci_upper_limit>-2.29</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.074</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-0.98</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.54</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.05</ci_lower_limit>
            <ci_upper_limit>0.09</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain Relief (PAR) Scores at 3 Hours Post Dose</title>
        <description>Pain relief is the amount of pain relief on a scale of 1-10 (where 1=no relief and 10=complete relief).</description>
        <time_frame>3 hours post dose</time_frame>
        <population>Analysis is based on the Intent-to-Treat (ITT) population, which included all subjects who were randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Three placebo capsules taken orally</description>
          </group>
          <group group_id="O2">
            <title>Acetaminophen 1000 mg</title>
            <description>Two encapsulated 500 mg tablets and one placebo capsule taken orally</description>
          </group>
          <group group_id="O3">
            <title>JNJ-10450232 250 mg</title>
            <description>One JNJ-10450232 250 mg capsule and two placebo capsules taken orally</description>
          </group>
          <group group_id="O4">
            <title>JNJ-10450232 1000 mg</title>
            <description>One JNJ-10450232 250 mg capsule, one JNJ-10450232 750 mg capsule, and one placebo capsule taken orally</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Relief (PAR) Scores at 3 Hours Post Dose</title>
          <description>Pain relief is the amount of pain relief on a scale of 1-10 (where 1=no relief and 10=complete relief).</description>
          <population>Analysis is based on the Intent-to-Treat (ITT) population, which included all subjects who were randomized.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="67"/>
                <count group_id="O3" value="69"/>
                <count group_id="O4" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.59" spread="0.42"/>
                    <measurement group_id="O2" value="5.39" spread="0.42"/>
                    <measurement group_id="O3" value="2.90" spread="0.41"/>
                    <measurement group_id="O4" value="5.40" spread="0.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>3.80</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.59</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.63</ci_lower_limit>
            <ci_upper_limit>4.97</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.026</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>1.32</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.59</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.16</ci_lower_limit>
            <ci_upper_limit>2.48</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>3.82</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.60</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.64</ci_lower_limit>
            <ci_upper_limit>4.99</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-2.48</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.59</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.64</ci_lower_limit>
            <ci_upper_limit>-1.32</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.978</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>0.02</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.60</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.16</ci_lower_limit>
            <ci_upper_limit>1.19</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain Relief (PAR) Scores at 4 Hours Post Dose</title>
        <description>Pain relief is the amount of pain relief on a scale of 1-10 (where 1=no relief and 10=complete relief).</description>
        <time_frame>4 hours post dose</time_frame>
        <population>Analysis is based on the Intent-to-Treat (ITT) population, which included all subjects who were randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Three placebo capsules taken orally</description>
          </group>
          <group group_id="O2">
            <title>Acetaminophen 1000 mg</title>
            <description>Two encapsulated 500 mg tablets and one placebo capsule taken orally</description>
          </group>
          <group group_id="O3">
            <title>JNJ-10450232 250 mg</title>
            <description>One JNJ-10450232 250 mg capsule and two placebo capsules taken orally</description>
          </group>
          <group group_id="O4">
            <title>JNJ-10450232 1000 mg</title>
            <description>One JNJ-10450232 250 mg capsule, one JNJ-10450232 750 mg capsule, and one placebo capsule taken orally</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Relief (PAR) Scores at 4 Hours Post Dose</title>
          <description>Pain relief is the amount of pain relief on a scale of 1-10 (where 1=no relief and 10=complete relief).</description>
          <population>Analysis is based on the Intent-to-Treat (ITT) population, which included all subjects who were randomized.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="67"/>
                <count group_id="O3" value="69"/>
                <count group_id="O4" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.92" spread="0.44"/>
                    <measurement group_id="O2" value="5.31" spread="0.44"/>
                    <measurement group_id="O3" value="2.99" spread="0.43"/>
                    <measurement group_id="O4" value="5.83" spread="0.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>3.40</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.62</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.18</ci_lower_limit>
            <ci_upper_limit>4.62</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.081</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>1.07</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.61</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.13</ci_lower_limit>
            <ci_upper_limit>2.28</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>3.91</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.62</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.69</ci_lower_limit>
            <ci_upper_limit>5.14</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-2.32</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.61</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.53</ci_lower_limit>
            <ci_upper_limit>-1.11</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.407</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>0.52</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.62</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.71</ci_lower_limit>
            <ci_upper_limit>1.74</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain Relief (PAR) Scores at 5 Hours Post Dose</title>
        <description>Pain relief is the amount of pain relief on a scale of 1-10 (where 1=no relief and 10=complete relief).</description>
        <time_frame>5 hours post dose</time_frame>
        <population>Analysis is based on the Intent-to-Treat (ITT) population, which included all subjects who were randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Three placebo capsules taken orally</description>
          </group>
          <group group_id="O2">
            <title>Acetaminophen 1000 mg</title>
            <description>Two encapsulated 500 mg tablets and one placebo capsule taken orally</description>
          </group>
          <group group_id="O3">
            <title>JNJ-10450232 250 mg</title>
            <description>One JNJ-10450232 250 mg capsule and two placebo capsules taken orally</description>
          </group>
          <group group_id="O4">
            <title>JNJ-10450232 1000 mg</title>
            <description>One JNJ-10450232 250 mg capsule, one JNJ-10450232 750 mg capsule, and one placebo capsule taken orally</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Relief (PAR) Scores at 5 Hours Post Dose</title>
          <description>Pain relief is the amount of pain relief on a scale of 1-10 (where 1=no relief and 10=complete relief).</description>
          <population>Analysis is based on the Intent-to-Treat (ITT) population, which included all subjects who were randomized.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="67"/>
                <count group_id="O3" value="69"/>
                <count group_id="O4" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.17" spread="0.45"/>
                    <measurement group_id="O2" value="5.00" spread="0.45"/>
                    <measurement group_id="O3" value="3.05" spread="0.45"/>
                    <measurement group_id="O4" value="5.77" spread="0.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>2.83</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.64</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.56</ci_lower_limit>
            <ci_upper_limit>4.10</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.170</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>0.88</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.64</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.38</ci_lower_limit>
            <ci_upper_limit>2.14</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>3.60</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.65</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.33</ci_lower_limit>
            <ci_upper_limit>4.87</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.002</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-1.95</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.64</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.21</ci_lower_limit>
            <ci_upper_limit>-0.69</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.235</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>0.77</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.65</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.50</ci_lower_limit>
            <ci_upper_limit>2.04</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain Relief (PAR) Scores at 6 Hours Post Dose</title>
        <description>Pain relief is the amount of pain relief on a scale of 1-10 (where 1=no relief and 10=complete relief).</description>
        <time_frame>6 hours post dose</time_frame>
        <population>Analysis is based on the Intent-to-Treat (ITT) population, which included all subjects who were randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Three placebo capsules taken orally</description>
          </group>
          <group group_id="O2">
            <title>Acetaminophen 1000 mg</title>
            <description>Two encapsulated 500 mg tablets and one placebo capsule taken orally</description>
          </group>
          <group group_id="O3">
            <title>JNJ-10450232 250 mg</title>
            <description>One JNJ-10450232 250 mg capsule and two placebo capsules taken orally</description>
          </group>
          <group group_id="O4">
            <title>JNJ-10450232 1000 mg</title>
            <description>One JNJ-10450232 250 mg capsule, one JNJ-10450232 750 mg capsule, and one placebo capsule taken orally</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Relief (PAR) Scores at 6 Hours Post Dose</title>
          <description>Pain relief is the amount of pain relief on a scale of 1-10 (where 1=no relief and 10=complete relief).</description>
          <population>Analysis is based on the Intent-to-Treat (ITT) population, which included all subjects who were randomized.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="67"/>
                <count group_id="O3" value="69"/>
                <count group_id="O4" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.32" spread="0.46"/>
                    <measurement group_id="O2" value="4.42" spread="0.46"/>
                    <measurement group_id="O3" value="2.92" spread="0.45"/>
                    <measurement group_id="O4" value="5.68" spread="0.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.001</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>2.10</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.65</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.82</ci_lower_limit>
            <ci_upper_limit>3.39</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.355</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>0.60</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.65</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.68</ci_lower_limit>
            <ci_upper_limit>1.87</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>3.36</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.65</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.07</ci_lower_limit>
            <ci_upper_limit>4.65</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.021</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-1.50</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.65</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.78</ci_lower_limit>
            <ci_upper_limit>-0.23</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.056</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>1.26</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.65</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.03</ci_lower_limit>
            <ci_upper_limit>2.55</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain Relief (PAR) Scores at 7 Hours Post Dose</title>
        <description>Pain relief is the amount of pain relief on a scale of 1-10 (where 1=no relief and 10=complete relief).</description>
        <time_frame>7 hours post dose</time_frame>
        <population>Analysis is based on the Intent-to-Treat (ITT) population, which included all subjects who were randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Three placebo capsules taken orally</description>
          </group>
          <group group_id="O2">
            <title>Acetaminophen 1000 mg</title>
            <description>Two encapsulated 500 mg tablets and one placebo capsule taken orally</description>
          </group>
          <group group_id="O3">
            <title>JNJ-10450232 250 mg</title>
            <description>One JNJ-10450232 250 mg capsule and two placebo capsules taken orally</description>
          </group>
          <group group_id="O4">
            <title>JNJ-10450232 1000 mg</title>
            <description>One JNJ-10450232 250 mg capsule, one JNJ-10450232 750 mg capsule, and one placebo capsule taken orally</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Relief (PAR) Scores at 7 Hours Post Dose</title>
          <description>Pain relief is the amount of pain relief on a scale of 1-10 (where 1=no relief and 10=complete relief).</description>
          <population>Analysis is based on the Intent-to-Treat (ITT) population, which included all subjects who were randomized.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="67"/>
                <count group_id="O3" value="69"/>
                <count group_id="O4" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.41" spread="0.46"/>
                    <measurement group_id="O2" value="3.62" spread="0.47"/>
                    <measurement group_id="O3" value="2.80" spread="0.46"/>
                    <measurement group_id="O4" value="5.57" spread="0.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.067</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>1.21</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.66</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.09</ci_lower_limit>
            <ci_upper_limit>2.50</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.547</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>0.39</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.65</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.89</ci_lower_limit>
            <ci_upper_limit>1.68</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>3.16</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.66</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.86</ci_lower_limit>
            <ci_upper_limit>4.46</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.214</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-0.81</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.65</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.10</ci_lower_limit>
            <ci_upper_limit>0.47</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.003</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>1.96</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.66</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.66</ci_lower_limit>
            <ci_upper_limit>3.26</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain Relief (PAR) Scores at 8 Hours Post Dose</title>
        <description>Pain relief is the amount of pain relief on a scale of 1-10 (where 1=no relief and 10=complete relief).</description>
        <time_frame>8 hours post dose</time_frame>
        <population>Analysis is based on the Intent-to-Treat (ITT) population, which included all subjects who were randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Three placebo capsules taken orally</description>
          </group>
          <group group_id="O2">
            <title>Acetaminophen 1000 mg</title>
            <description>Two encapsulated 500 mg tablets and one placebo capsule taken orally</description>
          </group>
          <group group_id="O3">
            <title>JNJ-10450232 250 mg</title>
            <description>One JNJ-10450232 250 mg capsule and two placebo capsules taken orally</description>
          </group>
          <group group_id="O4">
            <title>JNJ-10450232 1000 mg</title>
            <description>One JNJ-10450232 250 mg capsule, one JNJ-10450232 750 mg capsule, and one placebo capsule taken orally</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Relief (PAR) Scores at 8 Hours Post Dose</title>
          <description>Pain relief is the amount of pain relief on a scale of 1-10 (where 1=no relief and 10=complete relief).</description>
          <population>Analysis is based on the Intent-to-Treat (ITT) population, which included all subjects who were randomized.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="67"/>
                <count group_id="O3" value="69"/>
                <count group_id="O4" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.41" spread="0.45"/>
                    <measurement group_id="O2" value="3.10" spread="0.45"/>
                    <measurement group_id="O3" value="2.63" spread="0.44"/>
                    <measurement group_id="O4" value="5.62" spread="0.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.281</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>0.69</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.64</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.57</ci_lower_limit>
            <ci_upper_limit>1.95</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.729</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>0.22</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.63</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.03</ci_lower_limit>
            <ci_upper_limit>1.47</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>3.21</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.64</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.95</ci_lower_limit>
            <ci_upper_limit>4.47</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.459</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-0.47</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.63</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.72</ci_lower_limit>
            <ci_upper_limit>0.78</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>2.52</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.64</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.26</ci_lower_limit>
            <ci_upper_limit>3.78</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain Relief (PAR) Scores at 9 Hours Post Dose</title>
        <description>Pain relief is the amount of pain relief on a scale of 1-10 (where 1=no relief and 10=complete relief).</description>
        <time_frame>9 hours post dose</time_frame>
        <population>Analysis is based on the Intent-to-Treat (ITT) population, which included all subjects who were randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Three placebo capsules taken orally</description>
          </group>
          <group group_id="O2">
            <title>Acetaminophen 1000 mg</title>
            <description>Two encapsulated 500 mg tablets and one placebo capsule taken orally</description>
          </group>
          <group group_id="O3">
            <title>JNJ-10450232 250 mg</title>
            <description>One JNJ-10450232 250 mg capsule and two placebo capsules taken orally</description>
          </group>
          <group group_id="O4">
            <title>JNJ-10450232 1000 mg</title>
            <description>One JNJ-10450232 250 mg capsule, one JNJ-10450232 750 mg capsule, and one placebo capsule taken orally</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Relief (PAR) Scores at 9 Hours Post Dose</title>
          <description>Pain relief is the amount of pain relief on a scale of 1-10 (where 1=no relief and 10=complete relief).</description>
          <population>Analysis is based on the Intent-to-Treat (ITT) population, which included all subjects who were randomized.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="67"/>
                <count group_id="O3" value="69"/>
                <count group_id="O4" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.46" spread="0.46"/>
                    <measurement group_id="O2" value="2.73" spread="0.46"/>
                    <measurement group_id="O3" value="2.98" spread="0.45"/>
                    <measurement group_id="O4" value="5.50" spread="0.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.674</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>0.27</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.65</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.00</ci_lower_limit>
            <ci_upper_limit>1.55</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.417</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>0.52</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.64</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.74</ci_lower_limit>
            <ci_upper_limit>1.79</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>3.05</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.65</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.77</ci_lower_limit>
            <ci_upper_limit>4.33</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.698</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>0.25</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.64</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.02</ci_lower_limit>
            <ci_upper_limit>1.52</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>2.77</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.65</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.49</ci_lower_limit>
            <ci_upper_limit>4.05</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain Relief (PAR) Scores at 10 Hours Post Dose</title>
        <description>Pain relief is the amount of pain relief on a scale of 1-10 (where 1=no relief and 10=complete relief).</description>
        <time_frame>10 hours post dose</time_frame>
        <population>Analysis is based on the Intent-to-Treat (ITT) population, which included all subjects who were randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Three placebo capsules taken orally</description>
          </group>
          <group group_id="O2">
            <title>Acetaminophen 1000 mg</title>
            <description>Two encapsulated 500 mg tablets and one placebo capsule taken orally</description>
          </group>
          <group group_id="O3">
            <title>JNJ-10450232 250 mg</title>
            <description>One JNJ-10450232 250 mg capsule and two placebo capsules taken orally</description>
          </group>
          <group group_id="O4">
            <title>JNJ-10450232 1000 mg</title>
            <description>One JNJ-10450232 250 mg capsule, one JNJ-10450232 750 mg capsule, and one placebo capsule taken orally</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Relief (PAR) Scores at 10 Hours Post Dose</title>
          <description>Pain relief is the amount of pain relief on a scale of 1-10 (where 1=no relief and 10=complete relief).</description>
          <population>Analysis is based on the Intent-to-Treat (ITT) population, which included all subjects who were randomized.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="67"/>
                <count group_id="O3" value="69"/>
                <count group_id="O4" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.28" spread="0.46"/>
                    <measurement group_id="O2" value="2.67" spread="0.46"/>
                    <measurement group_id="O3" value="2.81" spread="0.45"/>
                    <measurement group_id="O4" value="5.40" spread="0.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.541</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>0.39</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.64</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.87</ci_lower_limit>
            <ci_upper_limit>1.66</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.409</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>0.53</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.64</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.73</ci_lower_limit>
            <ci_upper_limit>1.79</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>3.12</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.65</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.85</ci_lower_limit>
            <ci_upper_limit>4.39</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.834</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>0.13</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.64</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.12</ci_lower_limit>
            <ci_upper_limit>1.39</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>2.73</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.65</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.45</ci_lower_limit>
            <ci_upper_limit>4.00</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain Relief (PAR) Scores at 11 Hours Post Dose</title>
        <description>Pain relief is the amount of pain relief on a scale of 1-10 (where 1=no relief and 10=complete relief).</description>
        <time_frame>11 hours post dose</time_frame>
        <population>Analysis is based on the Intent-to-Treat (ITT) population, which included all subjects who were randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Three placebo capsules taken orally</description>
          </group>
          <group group_id="O2">
            <title>Acetaminophen 1000 mg</title>
            <description>Two encapsulated 500 mg tablets and one placebo capsule taken orally</description>
          </group>
          <group group_id="O3">
            <title>JNJ-10450232 250 mg</title>
            <description>One JNJ-10450232 250 mg capsule and two placebo capsules taken orally</description>
          </group>
          <group group_id="O4">
            <title>JNJ-10450232 1000 mg</title>
            <description>One JNJ-10450232 250 mg capsule, one JNJ-10450232 750 mg capsule, and one placebo capsule taken orally</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Relief (PAR) Scores at 11 Hours Post Dose</title>
          <description>Pain relief is the amount of pain relief on a scale of 1-10 (where 1=no relief and 10=complete relief).</description>
          <population>Analysis is based on the Intent-to-Treat (ITT) population, which included all subjects who were randomized.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="67"/>
                <count group_id="O3" value="69"/>
                <count group_id="O4" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.26" spread="0.45"/>
                    <measurement group_id="O2" value="2.63" spread="0.45"/>
                    <measurement group_id="O3" value="2.75" spread="0.45"/>
                    <measurement group_id="O4" value="5.25" spread="0.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.573</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>0.36</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.64</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.90</ci_lower_limit>
            <ci_upper_limit>1.63</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.448</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>0.49</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.64</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.77</ci_lower_limit>
            <ci_upper_limit>1.74</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>2.98</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.64</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.71</ci_lower_limit>
            <ci_upper_limit>4.25</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.848</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>0.12</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.64</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.13</ci_lower_limit>
            <ci_upper_limit>1.38</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>2.62</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.64</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.35</ci_lower_limit>
            <ci_upper_limit>3.89</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain Relief (PAR) Scores at 12 Hours Post Dose</title>
        <description>Pain relief is the amount of pain relief on a scale of 1-10 (where 1=no relief and 10=complete relief).</description>
        <time_frame>12 hours post dose</time_frame>
        <population>Analysis is based on the Intent-to-Treat (ITT) population, which included all subjects who were randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Three placebo capsules taken orally</description>
          </group>
          <group group_id="O2">
            <title>Acetaminophen 1000 mg</title>
            <description>Two encapsulated 500 mg tablets and one placebo capsule taken orally</description>
          </group>
          <group group_id="O3">
            <title>JNJ-10450232 250 mg</title>
            <description>One JNJ-10450232 250 mg capsule and two placebo capsules taken orally</description>
          </group>
          <group group_id="O4">
            <title>JNJ-10450232 1000 mg</title>
            <description>One JNJ-10450232 250 mg capsule, one JNJ-10450232 750 mg capsule, and one placebo capsule taken orally</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Relief (PAR) Scores at 12 Hours Post Dose</title>
          <description>Pain relief is the amount of pain relief on a scale of 1-10 (where 1=no relief and 10=complete relief).</description>
          <population>Analysis is based on the Intent-to-Treat (ITT) population, which included all subjects who were randomized.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="67"/>
                <count group_id="O3" value="69"/>
                <count group_id="O4" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.34" spread="0.46"/>
                    <measurement group_id="O2" value="2.57" spread="0.46"/>
                    <measurement group_id="O3" value="2.53" spread="0.45"/>
                    <measurement group_id="O4" value="5.16" spread="0.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.720</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>0.23</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.64</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.04</ci_lower_limit>
            <ci_upper_limit>1.50</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.763</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>0.19</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.64</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.07</ci_lower_limit>
            <ci_upper_limit>1.45</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>2.82</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.65</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.55</ci_lower_limit>
            <ci_upper_limit>4.09</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.952</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-0.04</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.64</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.30</ci_lower_limit>
            <ci_upper_limit>1.22</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>2.59</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.65</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.31</ci_lower_limit>
            <ci_upper_limit>3.86</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain Relief (PAR) Scores at 16 Hours Post Dose</title>
        <description>Pain relief is the amount of pain relief on a scale of 1-10 (where 1=no relief and 10=complete relief).</description>
        <time_frame>16 hours post dose</time_frame>
        <population>Analysis is based on the Intent-to-Treat (ITT) population, which included all subjects who were randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Three placebo capsules taken orally</description>
          </group>
          <group group_id="O2">
            <title>Acetaminophen 1000 mg</title>
            <description>Two encapsulated 500 mg tablets and one placebo capsule taken orally</description>
          </group>
          <group group_id="O3">
            <title>JNJ-10450232 250 mg</title>
            <description>One JNJ-10450232 250 mg capsule and two placebo capsules taken orally</description>
          </group>
          <group group_id="O4">
            <title>JNJ-10450232 1000 mg</title>
            <description>One JNJ-10450232 250 mg capsule, one JNJ-10450232 750 mg capsule, and one placebo capsule taken orally</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Relief (PAR) Scores at 16 Hours Post Dose</title>
          <description>Pain relief is the amount of pain relief on a scale of 1-10 (where 1=no relief and 10=complete relief).</description>
          <population>Analysis is based on the Intent-to-Treat (ITT) population, which included all subjects who were randomized.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="67"/>
                <count group_id="O3" value="69"/>
                <count group_id="O4" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.09" spread="0.45"/>
                    <measurement group_id="O2" value="2.23" spread="0.45"/>
                    <measurement group_id="O3" value="2.07" spread="0.44"/>
                    <measurement group_id="O4" value="4.96" spread="0.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.821</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>0.14</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.63</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.10</ci_lower_limit>
            <ci_upper_limit>1.39</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.978</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-0.02</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.63</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.25</ci_lower_limit>
            <ci_upper_limit>1.22</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>2.88</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.63</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.63</ci_lower_limit>
            <ci_upper_limit>4.13</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.799</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-0.16</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.63</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.39</ci_lower_limit>
            <ci_upper_limit>1.07</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>2.73</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.63</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.49</ci_lower_limit>
            <ci_upper_limit>3.98</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain Relief (PAR) Scores at 24 Hours Post Dose</title>
        <description>Pain relief is the amount of pain relief on a scale of 1-10 (where 1=no relief and 10=complete relief).</description>
        <time_frame>24 hours post dose</time_frame>
        <population>Analysis is based on the Intent-to-Treat (ITT) population, which included all subjects who were randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Three placebo capsules taken orally</description>
          </group>
          <group group_id="O2">
            <title>Acetaminophen 1000 mg</title>
            <description>Two encapsulated 500 mg tablets and one placebo capsule taken orally</description>
          </group>
          <group group_id="O3">
            <title>JNJ-10450232 250 mg</title>
            <description>One JNJ-10450232 250 mg capsule and two placebo capsules taken orally</description>
          </group>
          <group group_id="O4">
            <title>JNJ-10450232 1000 mg</title>
            <description>One JNJ-10450232 250 mg capsule, one JNJ-10450232 750 mg capsule, and one placebo capsule taken orally</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Relief (PAR) Scores at 24 Hours Post Dose</title>
          <description>Pain relief is the amount of pain relief on a scale of 1-10 (where 1=no relief and 10=complete relief).</description>
          <population>Analysis is based on the Intent-to-Treat (ITT) population, which included all subjects who were randomized.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="67"/>
                <count group_id="O3" value="69"/>
                <count group_id="O4" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.44" spread="0.49"/>
                    <measurement group_id="O2" value="2.20" spread="0.50"/>
                    <measurement group_id="O3" value="2.33" spread="0.49"/>
                    <measurement group_id="O4" value="4.96" spread="0.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.726</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-0.25</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.70</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.62</ci_lower_limit>
            <ci_upper_limit>1.13</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.869</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-0.11</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.69</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.48</ci_lower_limit>
            <ci_upper_limit>1.25</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>2.52</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.70</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.13</ci_lower_limit>
            <ci_upper_limit>3.90</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.851</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>0.13</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.69</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.24</ci_lower_limit>
            <ci_upper_limit>1.50</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>2.76</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.70</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.38</ci_lower_limit>
            <ci_upper_limit>4.15</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Pain Relief After Dosing (Time to Rescue Medication)</title>
        <description>Time (minutes) to rescue medication was measured as the elapsed time from when the investigational product was given until the time rescue medication was given.</description>
        <time_frame>Completed at time of the first rescue medication (hours post dose), estimated up through Day 2</time_frame>
        <population>Analysis is based on the Intent-to-Treat (ITT) population, which included all subjects who were randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Three placebo capsules taken orally</description>
          </group>
          <group group_id="O2">
            <title>Acetaminophen 1000 mg</title>
            <description>Two encapsulated 500 mg tablets and one placebo capsule taken orally</description>
          </group>
          <group group_id="O3">
            <title>JNJ-10450232 250 mg</title>
            <description>One JNJ-10450232 250 mg capsule and two placebo capsules taken orally</description>
          </group>
          <group group_id="O4">
            <title>JNJ-10450232 1000 mg</title>
            <description>One JNJ-10450232 250 mg capsule, one JNJ-10450232 750 mg capsule, and one placebo capsule taken orally</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Pain Relief After Dosing (Time to Rescue Medication)</title>
          <description>Time (minutes) to rescue medication was measured as the elapsed time from when the investigational product was given until the time rescue medication was given.</description>
          <population>Analysis is based on the Intent-to-Treat (ITT) population, which included all subjects who were randomized.</population>
          <units>minutes</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="67"/>
                <count group_id="O3" value="69"/>
                <count group_id="O4" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="109.0" lower_limit="97.0" upper_limit="189.0"/>
                    <measurement group_id="O2" value="468.5" lower_limit="370.0" upper_limit="607.0"/>
                    <measurement group_id="O3" value="129.0" lower_limit="100.0" upper_limit="725.0"/>
                    <measurement group_id="O4" value="NA" lower_limit="768.0" upper_limit="NA">Median and upper limit of the confidence interval were not estimable since less than 50% of the subjects treated with JNJ-10450232 1000 mg used rescue medication.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups. Subjects who withdrew from the study before 24 hours, but did not use rescue therapy, were censored at the time of discontinuation. Subjects who did not rescue medication during the 24-hour study period had their time to rescue set to 24 hours and were censored at 24 hours.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.042</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided). P-Value is from Log-rank test comparing survival curves.</p_value_desc>
            <method>Log Rank</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups. Subjects who withdrew from the study before 24 hours, but did not use rescue therapy, were censored at the time of discontinuation. Subjects who did not rescue medication during the 24-hour study period had their time to rescue set to 24 hours and were censored at 24 hours.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.779</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided). P-Value is from Log-rank test comparing survival curves.</p_value_desc>
            <method>Log Rank</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups. Subjects who withdrew from the study before 24 hours, but did not use rescue therapy, were censored at the time of discontinuation. Subjects who did not rescue medication during the 24-hour study period had their time to rescue set to 24 hours and were censored at 24 hours.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided). P-Value is from Log-rank test comparing survival curves.</p_value_desc>
            <method>Log Rank</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups. Subjects who withdrew from the study before 24 hours, but did not use rescue therapy, were censored at the time of discontinuation. Subjects who did not rescue medication during the 24-hour study period had their time to rescue set to 24 hours and were censored at 24 hours.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.196</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided). P-Value is from Log-rank test comparing survival curves.</p_value_desc>
            <method>Log Rank</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups. Subjects who withdrew from the study before 24 hours, but did not use rescue therapy, were censored at the time of discontinuation. Subjects who did not rescue medication during the 24-hour study period had their time to rescue set to 24 hours and were censored at 24 hours.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.006</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided). P-Value is from Log-rank test comparing survival curves.</p_value_desc>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subject Global Evaluation</title>
        <description>How the subject would rate the study medication as a pain-reliever on a scale of 0-4 (where 0=poor and 4=excellent).</description>
        <time_frame>Completed at hour 12 or at time of the first rescue medication (hours post dose).</time_frame>
        <population>Analysis is based on the Intent-to-Treat (ITT) population, which included all subjects who were randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Three placebo capsules taken orally</description>
          </group>
          <group group_id="O2">
            <title>Acetaminophen 1000 mg</title>
            <description>Two encapsulated 500 mg tablets and one placebo capsule taken orally</description>
          </group>
          <group group_id="O3">
            <title>JNJ-10450232 250 mg</title>
            <description>One JNJ-10450232 250 mg capsule and two placebo capsules taken orally</description>
          </group>
          <group group_id="O4">
            <title>JNJ-10450232 1000 mg</title>
            <description>One JNJ-10450232 250 mg capsule, one JNJ-10450232 750 mg capsule, and one placebo capsule taken orally</description>
          </group>
        </group_list>
        <measure>
          <title>Subject Global Evaluation</title>
          <description>How the subject would rate the study medication as a pain-reliever on a scale of 0-4 (where 0=poor and 4=excellent).</description>
          <population>Analysis is based on the Intent-to-Treat (ITT) population, which included all subjects who were randomized.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="67"/>
                <count group_id="O3" value="69"/>
                <count group_id="O4" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Poor (0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.7"/>
                    <measurement group_id="O2" value="12.1"/>
                    <measurement group_id="O3" value="55.1"/>
                    <measurement group_id="O4" value="28.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fair (1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.9"/>
                    <measurement group_id="O2" value="9.1"/>
                    <measurement group_id="O3" value="4.3"/>
                    <measurement group_id="O4" value="6.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Good (2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.9"/>
                    <measurement group_id="O2" value="30.3"/>
                    <measurement group_id="O3" value="21.7"/>
                    <measurement group_id="O4" value="22.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very Good (3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.4"/>
                    <measurement group_id="O2" value="42.4"/>
                    <measurement group_id="O3" value="15.9"/>
                    <measurement group_id="O4" value="30.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Excellent (4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="6.1"/>
                    <measurement group_id="O3" value="2.9"/>
                    <measurement group_id="O4" value="12.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>1.5</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.21</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.1</ci_lower_limit>
            <ci_upper_limit>1.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.077</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>0.4</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.21</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.0</ci_lower_limit>
            <ci_upper_limit>0.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>1.2</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.21</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.8</ci_lower_limit>
            <ci_upper_limit>1.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-1.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.21</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.6</ci_lower_limit>
            <ci_upper_limit>-0.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.148</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and baseline pain categorical score were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-0.3</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.21</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.7</ci_lower_limit>
            <ci_upper_limit>0.1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Within 7 days after dental surgery, +30 days for serious adverse events.</time_frame>
      <desc>Adverse events (AEs) were systematically collected during the study and during the adverse event follow-up telephone interview within 7 days after dental surgery. Serious AEs were reported through 30 days after product use. Spontaneously reported AEs collected outside of the regularly scheduled telephone interviews were also recorded. Any clinically important abnormalities or causally-related AEs events persisting were followed until resolution or until reaching a clinically stable endpoint.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Three placebo capsules taken orally</description>
        </group>
        <group group_id="E2">
          <title>Acetaminophen 1000 mg</title>
          <description>Two encapsulated 500 mg tablets and one placebo capsule taken orally</description>
        </group>
        <group group_id="E3">
          <title>JNJ-10450232 250 mg</title>
          <description>One JNJ-10450232 250 mg capsule and two placebo capsules taken orally</description>
        </group>
        <group group_id="E4">
          <title>JNJ-10450232 1000 mg</title>
          <description>One JNJ-10450232 250 mg capsule, one JNJ-10450232 750 mg capsule, and one placebo capsule taken orally</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 16.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="67"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood Bilirubin Increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="67"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Joseph Aquilina, MD, Senior Director, Clinical Research</name_or_title>
      <organization>McNeil Consumer Healthcare Division of McNEIL-PPC, Inc.</organization>
      <phone>(215) 273-8025</phone>
      <email>JAquilin@its.jnj.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT02209181
org study id: CO-131230135611-CTPA
nct id: NCT02209181
lead sponsor: 
has dmc: No
To assess the safety and effectiveness one dose of a new pain reliever medicine (JNJ-10450232
      at either the 250 or 1000 mg strength) compared with placebo (sugar pill) or acetaminophen
      1000 mg after surgical removal of third molars. The primary endpoint will evaluate pain
      relief effectiveness up to 6 hours after administration of the study drug.
This is a single-center, randomized, double-blind, placebo- and active-controlled, parallel
      group study to evaluate the efficacy, safety and pharmacokinetic profile of JNJ-10450232,
      administered as a single dose in capsules (250 or 1000 mg), over a 24 hour period after molar
      extractions. Subjects will stay at the research center for ~24 hours after administration of
      study drug. Healthy male subjects, ages 18 to 45 years inclusive, will be screened by medical
      history, vital signs, an electrocardiogram (ECG), and clinical laboratory tests. Eligible
      subjects will return to the clinic on the day of surgery and complete baseline vital signs
      and clinical laboratory tests. They will undergo dental extraction of a minimum of three
      third-molars and, if qualified, will be randomly assigned to one of four study treatments for
      pain.
allocation: Randomized
intervention model: Parallel Assignment
primary purpose: Treatment
masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
measure: Analgesic Efficacy From 0 to 6 Hours After the Dose Using the Time-weighted Sum of Pain Intensity Difference (SPID 0-6)
time frame: 6 Hours
description: Time-weighted sum of pain intensity difference by first multiplying each pain intensity difference (PID) score by the time from the previous time point, and adding them together for each scheduled time point within 0-6 hours. Time points included 15 minutes, 30 minutes, 45 minutes, 1 hour, 1.5 hours, 2 hours, 3 hours, 4 hours, 5 hours, and 6 hours. The minimum SPID 0-6 was -30 and the maximum SPID 0-6 was 60, where higher is better. Pain intensity is the amount of pain experienced on a scale of 1-10 (where 1=no pain and 10=very severe pain).
measure: Pain Intensity Difference From Baseline (PID) Scores at 15 Minutes Post Dose
time frame: Baseline to 15 minutes post dose
description: Pain intensity is the amount of pain experienced on a scale of 1-10 (where 1=no pain and 10=very severe pain). The PID will be derived by subtracting the pain intensity from the baseline pain intensity.
measure: Pain Intensity Difference From Baseline (PID) Scores at 30 Minutes Post Dose
time frame: Baseline to 30 minutes post dose
description: Pain intensity is the amount of pain experienced on a scale of 1-10 (where 1=no pain and 10=very severe pain). The PID will be derived by subtracting the pain intensity from the baseline pain intensity.
measure: Pain Intensity Difference From Baseline (PID) Scores at 45 Minutes Post Dose
time frame: Baseline to 45 minutes post dose
description: Pain intensity is the amount of pain experienced on a scale of 1-10 (where 1=no pain and 10=very severe pain). The PID will be derived by subtracting the pain intensity from the baseline pain intensity.
measure: Pain Intensity Difference From Baseline (PID) Scores at 1 Hour Post Dose
time frame: Baseline to 1 hour post dose
description: Pain intensity is the amount of pain experienced on a scale of 1-10 (where 1=no pain and 10=very severe pain). The PID will be derived by subtracting the pain intensity from the baseline pain intensity.
measure: Pain Intensity Difference From Baseline (PID) Scores at 1.5 Hours Post Dose
time frame: Baseline to 1.5 hours post dose
description: Pain intensity is the amount of pain experienced on a scale of 1-10 (where 1=no pain and 10=very severe pain). The PID will be derived by subtracting the pain intensity from the baseline pain intensity.
measure: Pain Intensity Difference From Baseline (PID) Scores at 2 Hours Post Dose
time frame: Baseline to 2 hours post dose
description: Pain intensity is the amount of pain experienced on a scale of 1-10 (where 1=no pain and 10=very severe pain). The PID will be derived by subtracting the pain intensity from the baseline pain intensity.
measure: Pain Intensity Difference From Baseline (PID) Scores at 3 Hours Post Dose
time frame: Baseline to 3 hours post dose
description: Pain intensity is the amount of pain experienced on a scale of 1-10 (where 1=no pain and 10=very severe pain). The PID will be derived by subtracting the pain intensity from the baseline pain intensity.
measure: Pain Intensity Difference From Baseline (PID) Scores at 4 Hours Post Dose
time frame: Baseline to 4 hours post dose
description: Pain intensity is the amount of pain experienced on a scale of 1-10 (where 1=no pain and 10=very severe pain). The PID will be derived by subtracting the pain intensity from the baseline pain intensity.
measure: Pain Intensity Difference From Baseline (PID) Scores at 5 Hours Post Dose
time frame: Baseline to 5 hours post dose
description: Pain intensity is the amount of pain experienced on a scale of 1-10 (where 1=no pain and 10=very severe pain). The PID will be derived by subtracting the pain intensity from the baseline pain intensity.
measure: Pain Intensity Difference From Baseline (PID) Scores at 6 Hours Post Dose
time frame: Baseline to 6 hours post dose
description: Pain intensity is the amount of pain experienced on a scale of 1-10 (where 1=no pain and 10=very severe pain). The PID will be derived by subtracting the pain intensity from the baseline pain intensity.
measure: Pain Intensity Difference From Baseline (PID) Scores at 7 Hours Post Dose
time frame: Baseline to 7 hours post dose
description: Pain intensity is the amount of pain experienced on a scale of 1-10 (where 1=no pain and 10=very severe pain). The PID will be derived by subtracting the pain intensity from the baseline pain intensity.
measure: Pain Intensity Difference From Baseline (PID) Scores at 8 Hours Post Dose
time frame: Baseline to 8 hours post dose
description: Pain intensity is the amount of pain experienced on a scale of 1-10 (where 1=no pain and 10=very severe pain). The PID will be derived by subtracting the pain intensity from the baseline pain intensity.
measure: Pain Intensity Difference From Baseline (PID) Scores at 9 Hours Post Dose
time frame: Baseline to 9 hours post dose
description: Pain intensity is the amount of pain experienced on a scale of 1-10 (where 1=no pain and 10=very severe pain). The PID will be derived by subtracting the pain intensity from the baseline pain intensity.
measure: Pain Intensity Difference From Baseline (PID) Scores at 10 Hours Post Dose
time frame: Baseline to 10 hours post dose
description: Pain intensity is the amount of pain experienced on a scale of 1-10 (where 1=no pain and 10=very severe pain). The PID will be derived by subtracting the pain intensity from the baseline pain intensity.
measure: Pain Intensity Difference From Baseline (PID) Scores at 11 Hours Post Dose
time frame: Baseline to 11 hours post dose
description: Pain intensity is the amount of pain experienced on a scale of 1-10 (where 1=no pain and 10=very severe pain). The PID will be derived by subtracting the pain intensity from the baseline pain intensity.
measure: Pain Intensity Difference From Baseline (PID) Scores at 12 Hours Post Dose
time frame: Baseline to 12 hours post dose
description: Pain intensity is the amount of pain experienced on a scale of 1-10 (where 1=no pain and 10=very severe pain). The PID will be derived by subtracting the pain intensity from the baseline pain intensity.
measure: Pain Intensity Difference From Baseline (PID) Scores at 16 Hours Post Dose
time frame: Baseline to 16 hours post dose
description: Pain intensity is the amount of pain experienced on a scale of 1-10 (where 1=no pain and 10=very severe pain). The PID will be derived by subtracting the pain intensity from the baseline pain intensity.
measure: Pain Intensity Difference From Baseline (PID) Scores at 24 Hours Post Dose
time frame: Baseline to 24 hours post dose
description: Pain intensity is the amount of pain experienced on a scale of 1-10 (where 1=no pain and 10=very severe pain). The PID will be derived by subtracting the pain intensity from the baseline pain intensity.
measure: Pain Relief (PAR) Scores at 15 Minutes Post Dose
time frame: 15 minutes post dose
description: Pain relief is the amount of pain relief on a scale of 1-10 (where 1=no relief and 10=complete relief).
measure: Pain Relief (PAR) Scores at 30 Minutes Post Dose
time frame: 30 minutes post dose
description: Pain relief is the amount of pain relief on a scale of 1-10 (where 1=no relief and 10=complete relief).
measure: Pain Relief (PAR) Scores at 45 Minutes Post Dose
time frame: 45 minutes post dose
description: Pain relief is the amount of pain relief on a scale of 1-10 (where 1=no relief and 10=complete relief).
measure: Pain Relief (PAR) Scores at 1 Hour Post Dose
time frame: 1 hour post dose
description: Pain relief is the amount of pain relief on a scale of 1-10 (where 1=no relief and 10=complete relief).
measure: Pain Relief (PAR) Scores at 1.5 Hours Post Dose
time frame: 1.5 hours post dose
description: Pain relief is the amount of pain relief on a scale of 1-10 (where 1=no relief and 10=complete relief).
measure: Pain Relief (PAR) Scores at 2 Hours Post Dose
time frame: 2 hours post dose
description: Pain relief is the amount of pain relief on a scale of 1-10 (where 1=no relief and 10=complete relief).
measure: Pain Relief (PAR) Scores at 3 Hours Post Dose
time frame: 3 hours post dose
description: Pain relief is the amount of pain relief on a scale of 1-10 (where 1=no relief and 10=complete relief).
measure: Pain Relief (PAR) Scores at 4 Hours Post Dose
time frame: 4 hours post dose
description: Pain relief is the amount of pain relief on a scale of 1-10 (where 1=no relief and 10=complete relief).
measure: Pain Relief (PAR) Scores at 5 Hours Post Dose
time frame: 5 hours post dose
description: Pain relief is the amount of pain relief on a scale of 1-10 (where 1=no relief and 10=complete relief).
measure: Pain Relief (PAR) Scores at 6 Hours Post Dose
time frame: 6 hours post dose
description: Pain relief is the amount of pain relief on a scale of 1-10 (where 1=no relief and 10=complete relief).
measure: Pain Relief (PAR) Scores at 7 Hours Post Dose
time frame: 7 hours post dose
description: Pain relief is the amount of pain relief on a scale of 1-10 (where 1=no relief and 10=complete relief).
measure: Pain Relief (PAR) Scores at 8 Hours Post Dose
time frame: 8 hours post dose
description: Pain relief is the amount of pain relief on a scale of 1-10 (where 1=no relief and 10=complete relief).
measure: Pain Relief (PAR) Scores at 9 Hours Post Dose
time frame: 9 hours post dose
description: Pain relief is the amount of pain relief on a scale of 1-10 (where 1=no relief and 10=complete relief).
measure: Pain Relief (PAR) Scores at 10 Hours Post Dose
time frame: 10 hours post dose
description: Pain relief is the amount of pain relief on a scale of 1-10 (where 1=no relief and 10=complete relief).
measure: Pain Relief (PAR) Scores at 11 Hours Post Dose
time frame: 11 hours post dose
description: Pain relief is the amount of pain relief on a scale of 1-10 (where 1=no relief and 10=complete relief).
measure: Pain Relief (PAR) Scores at 12 Hours Post Dose
time frame: 12 hours post dose
description: Pain relief is the amount of pain relief on a scale of 1-10 (where 1=no relief and 10=complete relief).
measure: Pain Relief (PAR) Scores at 16 Hours Post Dose
time frame: 16 hours post dose
description: Pain relief is the amount of pain relief on a scale of 1-10 (where 1=no relief and 10=complete relief).
measure: Pain Relief (PAR) Scores at 24 Hours Post Dose
time frame: 24 hours post dose
description: Pain relief is the amount of pain relief on a scale of 1-10 (where 1=no relief and 10=complete relief).
measure: Duration of Pain Relief After Dosing (Time to Rescue Medication)
time frame: Completed at time of the first rescue medication (hours post dose), estimated up through Day 2
description: Time (minutes) to rescue medication was measured as the elapsed time from when the investigational product was given until the time rescue medication was given.
measure: Subject Global Evaluation
time frame: Completed at hour 12 or at time of the first rescue medication (hours post dose).
description: How the subject would rate the study medication as a pain-reliever on a scale of 0-4 (where 0=poor and 4=excellent).
arm group label: JNJ-10450232 250 mg
arm group type: Experimental
arm group label: JNJ-10450232 1000 mg
arm group type: Experimental
arm group label: Placebo
arm group type: Placebo Comparator
arm group label: Acetaminophen 1000 mg
arm group type: Active Comparator
intervention type: Drug
intervention name: JNJ-10450232 / Not yet marketed
description: Subjects who meet the randomization criteria at baseline within 4.5 hours after dental surgery will be assigned to one of four treatment groups stratified by pharmacokinetic blood sampling schedule and by baseline pain intensity level.
arm group label: JNJ-10450232 250 mg
intervention type: Drug
intervention name: JNJ-10450232 / Not yet marketed
description: Subjects who meet the randomization criteria at baseline within 4.5 hours after dental surgery will be assigned to one of four treatment groups stratified by pharmacokinetic blood sampling schedule and by baseline pain intensity level.
arm group label: JNJ-10450232 1000 mg
intervention type: Drug
intervention name: JNJ-10450232 / Not yet marketed
description: Subjects who meet the randomization criteria at baseline within 4.5 hours after dental surgery will be assigned to one of four treatment groups stratified by pharmacokinetic blood sampling schedule and by baseline pain intensity level.
arm group label: Placebo
intervention type: Drug
intervention name: acetaminophen / Tylenol
description: Subjects who meet the randomization criteria at baseline within 4.5 hours after dental surgery will be assigned to one of four treatment groups stratified by pharmacokinetic blood sampling schedule and by baseline pain intensity level.
arm group label: Acetaminophen 1000 mg
criteria: 
gender: Male
minimum age: 18 Years
maximum age: 45 Years
healthy volunteers: No
last name: Derek Muse, MD
role: Principal Investigator
affiliation: Jean Brown Research
last name: Cathy Gelotte, Ph.D.
role: Study Director
affiliation: McNeil Consumer Healthcare Division of McNEIL-PPC, Inc.
facility: 
country: United States
responsible party type: Sponsor
mesh term: Toothache
mesh term: Acetaminophen
participant flow: 
baseline: 
outcome list: 
reported events: 
certain agreements: 
point of contact: 